

**Attended Posters – Monday, 7 May 2007**

**P002-M LOSS OF ANION EXCHANGER 2 IN MICE RESULTS IN OSTEOPETROTIC LONG BONES, WHEREAS SKULL IS NOT AFFECTED**

I. D. Jansen\*<sup>1</sup>, T. J. de Vries<sup>1</sup>, J. Ravesloot<sup>2</sup>, V. Everts<sup>1</sup>, R. P. Oude Elferink<sup>3</sup>

<sup>1</sup>Periodontology and Oral Cell Biology, ACTA, <sup>2</sup>Physiology, <sup>3</sup>AMC Liver Center, Academic Medical Center, Amsterdam, Netherlands

**P005-M DIRECT RAB11-RAC1 INTERACTION REGULATES EXIT OF RECYCLING VESICLES FROM THE PERINUCLEAR COMPARTMENT IS INVOLVED IN CELLULAR MIGRATION**

Y. Sun\*<sup>1</sup>, B. G. Kalman<sup>1</sup>, H. K. Väänänen<sup>1</sup>

<sup>1</sup>Department of Anatomy, Institute of Biomedicine, University of Turku, Turku, Finland

**P008-M DIPHYLLIN, A NOVEL POTENT V-ATPASE INHIBITOR, ABROGATES ACIDIFICATION OF THE OSTEOCLASTIC RESORPTION LACUNAE AND BONE RESORPTION**

M. G. Sørensen\*<sup>1</sup>, K. Henriksen<sup>1</sup>, A. V. Neutzsky-Wulff<sup>1</sup>, C. Christiansen<sup>2</sup>, M. A. Karsdal<sup>1</sup>

<sup>1</sup>Pharmacology, Nordic Bioscience, <sup>2</sup>Center for Clinical and Basic Research, Herlev, Denmark

**P011-M BONE-DERIVED LIPIDS STIMULATE BREAST CANCER CELL GROWTH THROUGH A CROSSTALK BETWEEN FARNESOID X RECEPTOR AND ESTROGEN RECEPTOR: IN VITRO AND CLINICAL DATA**

F. Journe\*<sup>1</sup>, G. Laurent<sup>2</sup>, C. Chaboteaux<sup>1</sup>, D. Nonclercq<sup>2</sup>, V. Durbecq<sup>1</sup>, D. Larsimont<sup>1</sup>, J. Body<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, Institut Bordet, Brussels, <sup>2</sup>Laboratory of Histology, Université de Mons-Hainaut, Mons, Belgium

**P014-M THE PPAR GAMMA AGONIST PIOGLITAZONE EXAGGERATES BONE LOSS, WHILE THE PPAR ALPHA AGONIST FENOFIBRATE MAINTAINS BMD AND BONE ARCHITECTURE IN OVARECTOMIZED RATS**

A. K. Stunes\*<sup>1</sup>, B. Gustafsson<sup>2</sup>, R. Berge<sup>3</sup>, I. Westbroek<sup>4</sup>, J. E. Reseland<sup>5</sup>, U. Syversen<sup>1</sup>

<sup>1</sup>Dept of Cancer Research and Mol. Medicine, Norwegian University of Science and Technology, <sup>2</sup>Dept of Gastroenterology, St Olav's University Hospital HF, Trondheim, <sup>3</sup>Section of Medical Biochemistry, Institute of Medicine, University of Bergen, Bergen, Norway, <sup>4</sup>Internal Medicine and Orthopaedics, Erasmus MC, Rotterdam, Netherlands, <sup>5</sup>Dept of Biomaterials, Institute for Clinical Dentistry, University of Oslo, Oslo, Norway

**P017-M ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS AS MEDIATORS OF VARIOUS PROFIBROGENIC ACTIONS OF PARATHYROID HORMONE-RELATED PROTEIN IN THE KIDNEY**

J. A. Ardura\*<sup>1</sup>, R. Berruguete<sup>1</sup>, D. Rámila<sup>1</sup>, M. V. Alvarez-Arroyo<sup>1</sup>, P. Esbrit<sup>1</sup>

<sup>1</sup>Bone and Mineral Metabolism Laboratory, Fundación Jiménez Díaz Capió Group, Madrid, Spain

**P020-M STRONTIUM RANELATE COUNTERACTS THE DRAMATIC INCREASE OF ENDOCORTICAL RESORPTION IN MICE WITH A SEVERE OSTEOPOROSIS**

V. Geoffroy\*<sup>1</sup>, D. Chappard<sup>2</sup>, H. Libouban<sup>2</sup>, F. Pascaretti<sup>2</sup>, A. Ostertag<sup>1</sup>, M. C. De Vernejoul<sup>1</sup>

<sup>1</sup>INSERM U606, Hospital Lariboisiere, Paris, <sup>2</sup>EMI 0335, INSERM, Angers, France

**P023-M VARIATIONS IN THE LRP5 AND LRP6 GENES: ASSOCIATIONS WITH BONE MINERAL DENSITY IN SCOTTISH POSTMENOPAUSAL WOMEN**

C. A. Parsons\*<sup>1</sup>, H. M. Macdonald<sup>1</sup>, F. E. McGuigan<sup>2</sup>, A. Stewart<sup>1</sup>, S. H. Ralston<sup>3</sup>, D. M. Reid<sup>1</sup>

<sup>1</sup>Medicine and Therapeutics, University of Aberdeen Medical School, Aberdeen, United Kingdom, <sup>2</sup>Department of Orthopedics, Malmö University Hospital, Malmö, Sweden, <sup>3</sup>Molecular Medicine Centre, Western General Hospital, Edinburgh, United Kingdom

**P026-M THIGH MUSCLE AREA CORRELATES WITH BONE MINERAL DENSITY (BMD) IN HEALTHY MEN AT THE TIME OF PEAK BONE MASS-RESULTS FROM THE ODENSE ANDROGEN STUDY**

L. Frederiksen\*<sup>1</sup>, T. L. Nielsen<sup>1</sup>, K. Wraae<sup>1</sup>, C. Hagen<sup>1</sup>, M. Andersen<sup>1</sup>, K. Brixen<sup>1</sup>

<sup>1</sup>Endocrinology, Odense University Hospital, Odense, Denmark

**P029-M PARATHYROID HORMONE IS AN INDEPENDENT PREDICTOR OF FIBROBLAST GROWTH FACTOR-23 IN HEALTHY MEN: MROS SWEDEN**

R. Marsell\*<sup>1</sup>, E. Grundberg<sup>2</sup>, T. Krajisnik<sup>2</sup>, P. Westerberg<sup>2</sup>, H. Mallmin<sup>1</sup>, M. Karlsson<sup>3</sup>, D. Mellström<sup>4</sup>, E. Orwoll<sup>5</sup>, C. Ohlsson<sup>4</sup>, K. B. Jonsson<sup>1</sup>, Ö. Ljunggren<sup>2</sup>, T. Larsson<sup>2</sup>  
<sup>1</sup>Dep. of Surgical Sciences, <sup>2</sup>Dep. of Medical Sciences, Uppsala University Hospital, Uppsala, <sup>3</sup>Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Department of Or, Malmö University Hospital, Malmö, <sup>4</sup>Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>5</sup>Oregon Health & Science University, Oregon Health & Science University, Portland, United States

**P032-M HISTOMORPHOMETRIC AND MICRO-CT ANALYSIS OF BONE BIOPSIES AFTER 3 ANNUAL INFUSIONS OF ZOLEDRONIC ACID 5 MG: EVIDENCE FOR PRESERVATION OF BONE STRUCTURE AND REMODELING CAPACITY**

R. R. Recker<sup>1</sup>, P. D. Delmas<sup>2</sup>, I. Reid<sup>3</sup>, S. R. Boonen<sup>4</sup>, J. Halse<sup>5</sup>, J. Supronik<sup>6</sup>, P. Garcia<sup>7</sup>, F. Hartl<sup>8</sup>, P. Mesenbrink<sup>9</sup>, J. Gasser<sup>10</sup>, E. F. Eriksen\*<sup>8</sup>  
<sup>1</sup>Department of Endocrinology, Creighton University School of Medicine, Omaha, United States, <sup>2</sup>Department of Medicine, University Claude Bernard of Lyon, Lyon, France, <sup>3</sup>Faculty of Medicine and Health Sciences, Auckland University, Auckland, New Zealand, <sup>4</sup>Center for Metabolic Bone Diseases, Leuven University, Leuven, Belgium, <sup>5</sup>Betanien Medical Laboratory, Betanien Medical Center, Oslo, Norway, <sup>6</sup>Department of Medicine, Sniadecki Hospital, Bialystok, Poland, <sup>7</sup>Department of Medicine, Universitario de Monterrey, Monterrey, Mexico, <sup>8</sup>Department of Medicine, Novartis Pharma AG, Basel, Switzerland, <sup>9</sup>Biostatistics, Novartis Pharmaceuticals Corporation, East Hanover, United States, <sup>10</sup>Department of Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland

**P035-M EFFICACY AND SAFETY OF A NOVEL TRANSDERMAL LOW-DOSE ESTRADIOL DELIVERY SYSTEM (MENOSTAR) FOR THE PREVENTION OF POSTMENOPAUSAL BONE LOSS COMPARED WITH RALOXIFENE (EVISTA): A 2-YEAR RANDOMIZED CLINICAL TRIAL**

L. B. Tankó\*<sup>1</sup>, M. Schäfers<sup>2</sup>, C. Muysers<sup>2</sup>, C. Christiansen<sup>1</sup>  
<sup>1</sup>Clinical Research, Center for Clinical and Basic Research, Ballerup, Denmark, <sup>2</sup>Gynecology, Schering AG, Berlin, Germany

**P038-M TERIPARATIDE REDUCES THE RISK FOR NEW ADJACENT VERTEBRAL FRACTURES**

M. L. Bouxsein\*<sup>1</sup>, P. Chen<sup>2</sup>, E. V. Glass<sup>2</sup>, D. F. Kallmes<sup>3</sup>, B. H. Mitlak<sup>2</sup>  
<sup>1</sup>Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, <sup>2</sup>Lilly Research Labs, Eli Lilly and Company, Indianapolis, <sup>3</sup>Radiology, Mayo Clinic, Rochester, United States

**P042-M NANOSTRUCTURE OF GROWING BONES IN BIPHOSPHONATE TREATED PIGS**

M. H. Bünger<sup>1</sup>, L. Haisheng<sup>2</sup>, Z. Xuenong<sup>2</sup>, C. E. Bünger<sup>2</sup>, B. L. Langdahl<sup>3</sup>, F. Besenbacher<sup>1</sup>, J. S. Pedersen<sup>4</sup>, H. Birkedal\*<sup>4</sup>  
<sup>1</sup>Interdisciplinary Nanoscience Center (iNANO), University of Aarhus, <sup>2</sup>Orthopaedic Research Laboratory, <sup>3</sup>Department of Endocrinology and Metabolism C, Aarhus University Hospital, <sup>4</sup>Department of Chemistry, University of Aarhus, Aarhus, Denmark

**P045-M A METHACRYLATE POLYMER CONTAINING IODINATED MONOMER USABLE AS BONE CEMENT: RADIO-OPACITY, IN VITRO AND IN VIVO BIOCOMPATIBILITY**

C. Zaharia<sup>1</sup>, M. F. Moreau<sup>2</sup>, T. Zecheru<sup>1</sup>, B. Marculescu<sup>1</sup>, R. Filmon<sup>2</sup>, M. F. Basle<sup>2</sup>, D. Chappard\*<sup>2</sup>  
<sup>1</sup>, Univ. Politehnica, Bucharest, Romania, <sup>2</sup>INSERM, EMI 0335-LHEA, Faculté de Médecine, Angers, France

**P048-M TERIPARATIDE USE TO ACCELERATE FRACTURE REPAIR IN DELAYED HEALING OF COMPLEX FRACTURES IN MILITARY PERSONEL: A CLINICAL CASE**

L. Di Bisceglie<sup>1</sup>, G. Fata<sup>2</sup>, V. Di Molfetta\*<sup>3</sup>  
<sup>1</sup>Unità Operativa Intensiva di Riabilitazione Ortopedico-Traumatologica, Istituti Ospedalieri Don Uva Bisceglie, Bisceglie, Italy, <sup>2</sup>, <sup>3</sup>Unità Operativa Intensiva di Riabilitazione Ortopedico-Traumatologica, Istituti Ospedalieri "Don Uva" Bisceglie, Bisceglie, Italy

**P051-M THE RELATION BETWEEN MECHANICAL STIMULUS AND CELL RESPONSE IN TRABECULAR BONE REMODELING**

J. W. C. Dunlop\*<sup>1</sup>, M. A. Hartmann<sup>2</sup>, Y. Bréchet<sup>3</sup>, P. Fratzl<sup>1</sup>, R. Weinkamer<sup>1</sup>  
<sup>1</sup>Department of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, <sup>2</sup>Service de Chimie Moléculaire, C.E.A. Saclay, Gif-Sur-Yvette, <sup>3</sup>Groupe Physique du Métal, LTPCM-ENSEEG-INPG, Grenoble, France

**P054-M ULTRASOUND MACHINE ASSISTS DECALCIFICATION**

X. Guo<sup>1</sup>, Y. Zheng<sup>2</sup>, W. Lam\*<sup>1</sup>

<sup>1</sup>Department of Rehabilitation Sciences, <sup>2</sup>Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, Hong Kong Special Administrative Region of China

**P057-M A TWO-YEAR MODERATE INTENSE EXERCISE INTERVENTION PROGRAM IN PRE-PUBERTAL CHILDREN INFLUENCE BONE MINERAL ACCRUAL BUT NOT HIP STRUCTURE: TWO-YEAR PROSPECTIVE DATA FROM THE PEDIATRIC OSTEOPOROSIS PREVENTION (POP) STUDY**

G. Alwis\*<sup>1</sup>, C. Lindén<sup>1</sup>, S. Stenevi-Lundgren<sup>1</sup>, H. Ahlborg<sup>1</sup>, P. Gardsell<sup>1</sup>, J. Besjakov<sup>1</sup>, M. K. Karlsson<sup>1</sup>

<sup>1</sup>Department of Orthopaedics, Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden

**P060-M VIRTUAL HISTOLOGY OF SOFT AND CALCIFIED TISSUES WITH A NOVEL MUTI-LENGTH SCALE CT, WITH RESOLUTION FROM MM TO SUB 30 NM**

S. Lau\*<sup>1</sup>, F. Duewer<sup>1</sup>, M. Feser<sup>1</sup>, W. Yun<sup>1</sup>, S. Ho<sup>2</sup>, B. Levkau<sup>3</sup>

<sup>1</sup>Applications Laboratory, Xradia Inc, Concord, <sup>2</sup>Preventive and Restorative Dental Sciences, UCSF, San Francisco, United States, <sup>3</sup>Institute of Pathophysiology, University Hospital Essen, Essen, Germany

**P063-M EXPRESSION OF WNT SIGNALING MOLECULES AT THE INJURED GROWTH PLATE CARTILAGE IN YOUNG RATS**

C. E. Macsai\*<sup>1</sup>, M. A. Scherer<sup>2</sup>, A. Zannettino<sup>3</sup>, B. K. Foster<sup>2</sup>, C. J. Xian<sup>2</sup>

<sup>1</sup>Discipline of Paediatrics, Faculty of Health Sciences, University of Adelaide, <sup>2</sup>Orthopaedic Surgery, Women's & Children's Hospital, North Adelaide, <sup>3</sup>Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia

**P066-M TITANIUM ORTHODONTIC MINIPLATES IN DOGS: ANCHORAGE EVALUATION WITH BONE MINERAL DENSITY MEASUREMENT**

M. Cornélis<sup>1</sup>, P. Mahy<sup>2</sup>, J. Devogelaer<sup>3</sup>, H. De Clerck<sup>4</sup>, B. Lengelé<sup>1</sup>, W. D'Hoore<sup>5</sup>, C. Nyssen-Behets\*<sup>1</sup>

<sup>1</sup>Experimental Morphology, Université Catholique de Louvain, <sup>2</sup>Maxillofacial Surgery, Université Catholique de Louvain, <sup>3</sup>Rheumatology, <sup>4</sup>Orthodontics, <sup>5</sup>Epidemiology, Biostatistics and Operational Methods in Public Health, Université Catholique de Louvain, Brussels, Belgium

**P069-M COMPARING THE EFFECTS OF EMDOGAIN (EMD), AMELOGENIN (AMEL) AND AMELOBLASTIN (AMBN) ON BONE GROWTH ONTO TITANIUM IMPLANTS**

E. A. Riksen\*<sup>1</sup>, H. Berner<sup>1</sup>, J. E. Ellingsen<sup>2</sup>, S. Lyngstadaas<sup>1</sup>, J. E. Reseland<sup>1</sup>

<sup>1</sup>Department of Biomaterial Research, <sup>2</sup>Oral Research Laboratory, University of Oslo, Oslo, Norway

**P072-M SEX-DEPENDENT EFFECT OF ALPHA-KETOGLUTARATE ADMINISTERED POSTNATALLY ON RIBS DEVELOPMENT IN PIGLETS PRENATALLY TREATED WITH DEXAMETHASONE**

E. Sliwa\*<sup>1</sup>, M. Tatar<sup>1</sup>, S. G. Pierzynowski<sup>2</sup>, T. Studzinski<sup>1</sup>

<sup>1</sup>Department of Animal Physiology, The Agricultural University of Lublin, Lublin, Poland, <sup>2</sup>Department of Cell and Organism Biology, Lund University, Lund, Sweden

**P075-M REGIONAL DIFFERENCES IN P2X7 RECEPTOR REGULATION OF BONE METABOLISM IN P2X7 KNOCK-OUT MICE**

S. Syberg\*<sup>1</sup>, S. Petersen<sup>1</sup>, N. R. Jørgensen<sup>1</sup>

<sup>1</sup>The Osteoporosis and Metabolic Bone Unit, Depts. of Endocrinology and Clinical Chemistry, Copenhagen University Hospital, HS, Hvidovre, Denmark

**P078-M MENOPAUSE-RELATED CHANGES IN THE RATE OF CORTICAL BONE RESORPTION INCLUDE CONSECUTIVE PHASES OF INCREASE, STABILISATION AND DECREASE**

E. I. Tolstykh\*<sup>1</sup>, N. B. Shagina<sup>1</sup>, M. O. Degteva<sup>1</sup>

<sup>1</sup>Biophysics Laboratory, Urals Research Center for Radiation Medicine, Chelyabinsk, Russian Federation

**P081-M THE EFFECT OF LOW INTENSITY PULSED ULTRASOUND ON THE HEALING OF RHBMP-4 INCORPORATED HYDROGEL GRAFT IN SPINAL FUSION**

X. Y. Wang\*<sup>1</sup>, X. Guo<sup>1</sup>, M. Q. Liu<sup>1</sup>, J. Y. C. Cheng<sup>2</sup>, Y. L. Mi<sup>3</sup>

<sup>1</sup>Rehabilitation Sciences, The Hong Kong Polytechnic University, <sup>2</sup>Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, <sup>3</sup>Department of Chemical Engineering, The Hong Kong University of Science and Technology, Hong Kong, China

**P084-M UTILITY OF ALPHA CTX AS AN INDEX OF VELOCITY OF SKELETAL GROWTH IN PREPUBERAL CHILDREN**

S. N. Zeni\*<sup>1</sup>, G. G. Pellegrini<sup>2</sup>, M. Linares<sup>3</sup>, N. Piazza<sup>4</sup>, J. Somoza<sup>1</sup>, M. E. Rio<sup>5</sup>

<sup>1</sup>Sección Osteopatías Médicas, Hospital de Clínicas, <sup>2</sup>Catedra Bioq.Gral. y Bucal, Fac. Odontología, Buenos Aires, <sup>3</sup>Epidemiology. Infantil Nutrition, Public Health Secretary, Vicente López, <sup>4</sup>Epidemiology. Infantil Nutrition., Public Health Secretary, Vicente Lopez, <sup>5</sup>Nutrition, School of Biochemistry and Pharmacy. UBA, Buenos Aires, Argentina

**P086-M ONCOSTATIN M SENSITIZES RAT OSTEOSARCOMA CELLS TO THE ANTI-TUMOR EFFECT OF PKC412**

C. Chipoy<sup>1</sup>, B. Brounais<sup>1</sup>, K. Mori<sup>1</sup>, S. Battaglia<sup>1</sup>, C. Richards<sup>2</sup>, D. Heymann<sup>1</sup>, F. Rédini<sup>1</sup>, F. Blanchard\*<sup>1</sup>  
<sup>1</sup>EA3822-Inserm ERI7, Faculté de Médecine, Nantes, France, <sup>2</sup>Center for Gene Therapeutics, McMaster University, Hamilton, Canada

**P089-M THE EXPRESSION OF BONE MORPHOGENETIC PROTEIN7 AND ITS RECEPTORS IN THE HUMAN NORMAL KIDNEY AND KIDNEY CANCER**

D. Bobinac\*<sup>1</sup>, I. Maric<sup>2</sup>, D. Markic<sup>3</sup>, O. Cvijanovic<sup>2</sup>, J. Spanjol<sup>4</sup>, T. Celic<sup>2</sup>, Z. Fuckar<sup>4</sup>  
<sup>1</sup>Department of Anatomy, Faculty of Medicine, University of Rijeka, <sup>2</sup>Department of Anatomy, Faculty of Medicine, University of Rijeka, <sup>3</sup>Department of Urology, Clinical Hospital Rijeka, <sup>4</sup>Department of Urology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

**P092-M A GENE EXPRESSION SIGNATURE FROM BONE METASTASES AS PREDICTOR OF CLINICAL OUTCOME IN BREAST CANCER PATIENTS**

M. Capulli\*<sup>1</sup>, N. Rucci<sup>1</sup>, A. Angelucci<sup>2</sup>, F. Martella<sup>3</sup>, M. Bologna<sup>4</sup>, K. Driouch<sup>5</sup>, T. Landemaine<sup>5</sup>, R. Lidereau<sup>5</sup>, P. Clement-Lacroix<sup>6</sup>, T. Garcia<sup>6</sup>, A. Teti<sup>1</sup>, E. Ricevuto<sup>3</sup>  
<sup>1</sup>Department of Experimental Medicine, <sup>2</sup>Department of Surgery, <sup>3</sup>U.O. Medical Oncology, San Salvatore Hospital, <sup>4</sup>Department of Basic and Applied Biology, University of L'Aquila, L'Aquila, Italy, <sup>5</sup>Oncogenetic Laboratory, Centre René Huguenin, Institut National de la Santé et de la Recherche Médicale, St Cloud, <sup>6</sup>In Vivo Pharmacology, Prostrakan, Romainville, France

**P095-M IMMUNOHISTOCHEMISTRY OF BONE MORPHOGENETIC PROTEIN-9 IN HUMAN LIVER**

O. Cvijanovic\*<sup>1</sup>, I. Maric<sup>1</sup>, Z. Crncevic-Orlic<sup>2</sup>, D. Cekinovic<sup>3</sup>, S. Zoricic<sup>1</sup>, D. Bobinac<sup>1</sup>  
<sup>1</sup>Department of Anatomy, Medical Faculty University in Rijeka, <sup>2</sup>Department of Internal Medicine, Clinical Hospital Rijeka, <sup>3</sup>Department of Histology, Medical Faculty University in Rijeka, Rijeka, Croatia

**P098-M SYNDECAN-2 IS INVOLVED IN THE APOPTOTIC RESPONSE TO CHEMOTHERAPEUTIC DRUGS IN OSTEOSARCOMA IN VITRO AND IN VIVO**

A. Orosco<sup>1</sup>, O. Fromiguet<sup>1</sup>, C. Bazille<sup>1</sup>, N. Entz-Werle<sup>2</sup>, P. J. Marie<sup>1</sup>, D. Modrowski\*<sup>1</sup>  
<sup>1</sup>Laboratory of Osteoblast Biology and Pathology, INSERM U606 and University Paris VII, Paris, <sup>2</sup>Dept of Biochemistry and Molecular Biology, CHRU Hautepierre, Strasbourg, France

**P101-M PARATHYROID HORMONE LEVELS, RENAL OSTEODYSTROPHY AND ECTOPIC CALCIFICATION IN HEMODIALYSIS PATIENTS**

M. Ioannou\*<sup>1</sup>, E. Gigas<sup>1</sup>, P. Ioannou<sup>2</sup>, N. Pekopoulos<sup>1</sup>, E. Limaxis<sup>1</sup>, S. Flesouras<sup>1</sup>  
<sup>1</sup>Department of Orthopaedic Surgery, General Hospital of Chalkis, Chalkis, Greece, <sup>2</sup>Department of Internal Medicine, Srh-Waldklinikum, Gera, Germany

**P104-M OSTEONECROSIS OF THE JAW UNDER BIPHOSPHONATE THERAPY – A GERMAN REGISTER FOR PATIENTS WITH OSTEONECROSIS OF THE JAW**

T. I. Jung\*<sup>1</sup>, J. Von der Gablentz<sup>1</sup>, D. Felsenberg<sup>1</sup>, B. Hoffmeister<sup>2</sup>, S. Mundlos<sup>3</sup>, M. Amling<sup>4</sup>, P. Fratzl<sup>5</sup>, M. J. Seibel<sup>6</sup>  
<sup>1</sup>Centre for Muscle and Bone Research ZMK, <sup>2</sup>Clinic for Oral, Maxillofacial and Plactical Surgery, Charite University Medicine, Campus Benjamin Franklin, <sup>3</sup>Institute for Medical Genetics, Charite University Medicine. Campus Virchow, Berlin, <sup>4</sup>Centre for Biomechanics and Skeletal Biology, University Hospital, Hamburg-Eppendorf, <sup>5</sup>Department of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam-Golm, Germany, <sup>6</sup>ANZAC Research Institute, University of Sydney, Sydney, Australia

**P107-M THERAPEUTIC RELEVANCE OF ZOLEDRONIC ACID IN PROSTATE CARCINOMA USING A NEW RAT SYNGENIC MODEL OF OSTEOBLASTIC METASTASES**

F. Lamoureux\*<sup>1</sup>, S. Battaglia<sup>1</sup>, M. Heymann<sup>2</sup>, P. Pilet<sup>3</sup>, F. Gouin<sup>4</sup>, F. Duteille<sup>5</sup>, D. Heymann<sup>1</sup>, F. Rédini<sup>1</sup>  
<sup>1</sup>WA 3822-INSERM ERI 7 Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses pr, Faculté de Médecine, <sup>2</sup>Service d'Anatomo-Pathologie, Hôpital Laennec, <sup>3</sup>U791 INSERM, Faculté de Chirurgie Dentaire, <sup>4</sup>Service d'Orthopédie, <sup>5</sup>Service de Chirurgie Plastique, CHU Hôtel Dieu, Nantes Cedex 1, France

**P110-M RANK LIGAND INHIBITION WITH OPG-FC ENHANCES THE INHIBITORY EFFECT OF**

**DOCETAXEL ON THE GROWTH OF PROSTATE CANCER PC-3 TUMORS IN THE MOUSE SKELETON**

R. Miller<sup>1</sup>, M. Roudier<sup>1</sup>, J. Jones<sup>1</sup>, M. Tometsko<sup>1</sup>, A. Armstrong<sup>1</sup>, J. Canon<sup>2</sup>, W. Dougall\*<sup>1</sup>

<sup>1</sup>, Amgen Inc., Seattle, <sup>2</sup>, Amgen Inc., Thousand Oaks, CA, United States

**P113-M BREAST CANCER CELLS INDUCE SPONTANEOUS OSTEOCLASTOGENESIS IN HUMAN COCULTURE SYSTEM**

V. Nicolini\*<sup>1</sup>, G. Baldini<sup>2</sup>, B. Martinelli<sup>3</sup>, P. Narducci<sup>2</sup>

<sup>1</sup>Biomedicine, University of Trieste, <sup>2</sup>Biomedicine, <sup>3</sup>U.C.O. of Clinical Orthopedics and Traumatology, University of Trieste, Trieste, Italy

**P116-M TERIPARATIDE IN OSTEOGENESIS IMPERFECTA: TREATMENT RESULTS OF AN 18 MONTHS PROSPECTIVE OBSERVATIONAL STUDY**

J. D. Ringe<sup>1</sup>, A. Dorst<sup>1</sup>, H. Faber<sup>1</sup>, P. Farahmand\*<sup>1</sup>

<sup>1</sup>Medizinische Klinik 4, Klinikum Leverkusen, University of Cologne, Leverkusen, Germany

**P119-M BONE LOSS IN THE COURSE OF THREE YEARS AFTER KIDNEY TRANSPLANTATION**

R. Smalcelj\*<sup>1</sup>, V. Kusec<sup>2</sup>, P. Kes<sup>1</sup>

<sup>1</sup>Dept of Dialysis, <sup>2</sup>Clin Inst Lab Diagnosis, Clinical Hospital Centre Zagreb, Zagreb, Croatia

**P122-M LONG-TERM NORMALIZATION OF BONE REMODELLING WITH A SINGLE INFUSION OF ZOLEDRONIC ACID IN A SEVERE, MULTIFOCAL, BIOLOGICALLY ACTIVE PAGET'S DISEASE OF BONE, RESISTANT TO TREATMENTS: A CASE REPORT**

B. F. Uebelhart\*<sup>1</sup>, P. Casez<sup>2</sup>, R. Rizzoli<sup>2</sup>

<sup>1</sup>Rehabilitation and Geriatrics, Cantonal Hospital, Geneva 14, <sup>2</sup>Rehabilitation and Geriatrics, Cantonal Hospital, Geneva, Switzerland

**P125-M EFFECT OF ALENDRONATE ON CYTOSKELETAL ORGANIZATION AND DYNAMICS OF ACTIN IN PC-3 PROSTATE CANCER CELLS**

S. S. Virtanen\*<sup>1</sup>, J. Sandholm<sup>2</sup>, K. Väänänen<sup>1</sup>, P. L. Härkönen<sup>1</sup>

<sup>1</sup>Anatomy, Biomedicine, University of Turku, <sup>2</sup>CIC, Centre for Biotechnology, University of Turku and Åbo Academi University, Turku, Finland

**P128-M STRONTIUM RANELATE PROMOTES AN OSTEOCYTE-LIKE PHENOTYPE FROM HUMAN PRIMARY OSTEOBLASTS EX VIVO**

G. J. Atkins\*<sup>1</sup>, K. J. Welldon<sup>1</sup>, D. M. Findlay<sup>1</sup>

<sup>1</sup>Bone Cell Biology Laboratory, University of Adelaide, Adelaide, Australia

**P131-M ENHANCED RESPONSE OF BONE CELLS TO NOISY FLUID SHEAR STRESS**

R. G. Bacabac\*<sup>1</sup>, J. J. W. A. van Loon<sup>1</sup>, T. H. Smit<sup>2</sup>, J. Klein-Nulend<sup>1</sup>

<sup>1</sup>Oral Cell Biology, ACTA-Vrije Universiteit, <sup>2</sup>Physics and Medical Technology, VU University Medical Center, Amsterdam, Netherlands

**P134-M THE EFFECTS OF SURAMIN ON LYSYL OXIDASE (LOX), TELOMERASE ACTIVITY AND THE DIFFERENTIATION OF OSTEOSARCOMA CELLS**

B. Buchinger\*<sup>1</sup>, F. Varga<sup>1</sup>, S. Spitzer<sup>1</sup>, K. Klaushofer<sup>1</sup>

<sup>1</sup>Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 4<sup>th</sup> Medical Department, Hanusch Hospital V, Vienna, Austria

**P137-M IN VITRO AND EX VIVO ANALYSIS OF CHROMOSOME BREAKS IN MURINE OSTEOBLAST CELLS TREATED WITH INTERMITTENT PTH**

E. C. Oliveira<sup>1</sup>, C. H. M. Castro\*<sup>1</sup>, V. L. Szejnfeld<sup>1</sup>

<sup>1</sup>Rheumatology, Universidade Federal de São Paulo, São Paulo, Brazil

**P140-M THE INFLUENCE OF GLUCOSE AND INSULIN TO HUMAN OSTEOSARCOMA CELL LINE MG63**

M. Cheng<sup>1</sup>, D. C. Chen\*<sup>1</sup>, C. Y. Lu<sup>1</sup>, S. Q. Wei<sup>1</sup>

<sup>1</sup>Department of Endocrinology, West China Hospital, Cheng Du, China

**P143-M CONSEQUENCES OF ALTERED RHO/RHO KINASE SIGNALLING IN OSTEOBLAST DIFFERENTIATION**

A. E. Coudert\*<sup>1</sup>, G. Bluteau<sup>1</sup>, A. E. Grigoriadis<sup>1</sup>

<sup>1</sup>Craniofacial Development, King's College London, London, United Kingdom

**P146-M DOWN REGULATION OF BETA-CATENIN AND TRANSDIFFERENTIATION OF HUMAN OSTEOBLASTS TO ADIPOCYTES UNDER ESTROGEN DEFICIENCY**

C. Foo<sup>1</sup>, S. Frey<sup>1</sup>, R. Zellweger<sup>2</sup>, L. Filgueira\*<sup>1</sup>

<sup>1</sup>Anatomy and Human Biology, University of Western Australia, Crawley, <sup>2</sup>Orthopaedic Surgery, Royal Perth Hospital, Perth, Australia

**P149-M IDENTIFICATION OF A FUNCTIONAL GENE INVOLVED IN MURINE BONE MARROW MESENCHYMAL CELL DIFFERENTIATION INTO OSTEOBLASTS**

Z. Hamidouche<sup>1</sup>, O. Fromigue\*<sup>1</sup>, E. Hay<sup>1</sup>, U. Nuber<sup>2</sup>, P. Charbord<sup>3</sup>, P. J. Marie<sup>1</sup>

<sup>1</sup>Laboratory of Osteoblast Biology and Pathology, INSERM U606 and University Paris VII, Paris, France,

<sup>2</sup>Max Planck Institute for Molecular Genetics, Berlin, Germany, <sup>3</sup>INSERM-ESPRI, Tours, France

**P152-M MORPHOLOGICAL AND BIOCHEMICAL CHARACTERIZATION OF BONE PHENOTYPE IN A CHONDRODYSPLASIA MOUSE MODEL**

B. Gualeni\*<sup>1</sup>, A. Rossi<sup>1</sup>, V. Geoffroy<sup>2</sup>, C. Marty-Morieux<sup>2</sup>, A. Forlino<sup>1</sup>, F. Pecora<sup>1</sup>, P. Houillier<sup>3</sup>, M. de Vernejoul<sup>2</sup>

<sup>1</sup>Department of Biochemistry, University of Pavia, Pavia, Italy, <sup>2</sup>Hopital Lariboisière, INSERM U606,

<sup>3</sup>Department of Physiology, Hopital Européen Georges Pompidou, Paris, France

**P155-M P2X7 RECEPTORS ARE IMPORTANT IN CELL SIGNALING AND PORE FORMATION IN MATURE PRIMARY HUMAN OSTEOBLASTS**

Z. Henriksen\*<sup>1</sup>, N. Nissen<sup>2</sup>, P. Schwarz<sup>3</sup>, T. K. Larsen<sup>4</sup>, N. R. Jørgensen<sup>1</sup>

<sup>1</sup>Osteoporosis Research Unit, Hvidovre University Hospital, Hvidovre, <sup>2</sup>Dep. of Orthopedic Surgery, Kolding and Fredricia Hospitals, Kolding, <sup>3</sup>Research Center for Ageing and Osteoporosis, <sup>4</sup>Dep. of Orthopedic Surgery, Glostrup University Hospital, Glostrup, Denmark

**P158-M BIOACTIVE PEPTIDES POSSESS BONE POTENTIAL BY IMPROVING OSTEOBLAST FUNCTION**

M. M. Huttunen\*<sup>1</sup>, M. Pekkinen<sup>1</sup>, M. E. B. Ahlström<sup>1</sup>, C. J. E. Lamberg-Allardt<sup>1</sup>

<sup>1</sup>Calcium Research Unit, University of Helsinki, Helsinki, Finland

**P161-M ULTRASTRUCTURAL STUDIES ON THE CENTRAL DARK LINE AND OCTACALCIUM PHOSPHATE**

M. Kakei\*<sup>1</sup>, T. Sakae<sup>2</sup>, H. Mishima<sup>3</sup>, M. Yoshikawa<sup>4</sup>

<sup>1</sup>Division of Oral Anatomy, Meikai Univ. School of Dentistry, Sakado, <sup>2</sup>Dept. of Histology, Embryology, Anatomy, Nihon Univ. School of Dentistry at Matsudo, Chiba, <sup>3</sup>Dept. of Health Science, Kochi Gakuen Collage, Kochi, <sup>4</sup>Division of Orthodontics, Meikai Univ. School of Dentistry, Sakado, Japan

**P164-M SCIATIC NERVE SECTION DECREASES CALLUS RESPONSE TO LOW INTENSITY PULSED ULTRASOUND**

W. Lam\*<sup>1</sup>, X. Guo<sup>1</sup>, K. Kwong<sup>1</sup>, K. Leung<sup>2</sup>

<sup>1</sup>Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, <sup>2</sup>Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region of China

**P167-M INTRACELLULAR ACCUMULATION OF ABNORMAL COLLAGEN CAUSES ER STRESS AND OSTEOBLAST APOPTOSIS IN A NEW MOUSE MODEL OF OSTEOGENESIS IMPERFECTA**

T. S. Lisse\*<sup>1</sup>, F. Thiele<sup>1</sup>, K. Abe<sup>2</sup>, W. Hans<sup>1</sup>, H. Fuchs<sup>1</sup>, S. H. Ralston<sup>3</sup>, M. Hrabe de Angelis<sup>1</sup>

<sup>1</sup>Institute of Experimental Genetics, GSF National Research Center, Neuherberg, Germany, <sup>2</sup>Department of Molecular Life Science, Tokai University, Kanagawa, Japan, <sup>3</sup>School of Molecular and Clinical Medicine, University of Edinburgh, Edinburgh, United Kingdom

**P170-M IN VIVO BONE FORMATION OF HUMAN EMBRYONIC STEM CELLS**

A. Mahmood\*<sup>1</sup>, B. Abdallah<sup>1</sup>, M. Kassem<sup>1</sup>

<sup>1</sup>Department of Endocrinology, Odense University Hospital, Odense, Denmark

**P173-M FRACTURE OF OSSIFIED POSTERIOR LONGITUDINAL LIGAMENT CAUSING CENTRAL CORD SYNDROME-A CASE REPORT**

S. Muthian\*<sup>1</sup>, E. B. Ahmed<sup>2</sup>

<sup>1</sup>Orthopaedics, University Hospital of North Staffordshire, <sup>2</sup>Orthopaedics, University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom

- P176-M REDUCTION IN MESENCHYMAL STEM CELL NUMBERS IN PREMATURE AGING DNA REPAIR DEFICIENT TTD MICE**  
 C. Nicolaije\*<sup>1</sup>, B. C. J. van der Eerden<sup>1</sup>, H. A. P. Pols<sup>1</sup>, J. H. J. Hoeijmakers<sup>2</sup>, G. T. J. van der Horst<sup>2</sup>, J. P. T. van Leeuwen<sup>1</sup>  
<sup>1</sup>Internal Medicine, <sup>2</sup>Genetics, Erasmus MC, Rotterdam, Netherlands
- P179-M EXPRESSION OF METALLOPROTEINASE-14 IS PLEIOTROPIC ON ALKALINE PHOSPHATASE EXPRESSION AND AFFECTS OSTEOGENIC DIFFERENTIATION**  
 D. Palmieri\*<sup>1</sup>, S. Soldano<sup>1</sup>, S. Zanotti<sup>1</sup>, D. Lombardini<sup>1</sup>, P. Manduca<sup>1</sup>  
<sup>1</sup>DiBio, University of Genova, Genova, Italy
- P182-M THE COGNITION ENHANCER ANIRACETAM INCREASES THE NUMBER OF OSTEOBLASTIC COLONIES IN MSC CULTURES WHEN COMBINED WITH FLUID SHEAR STRESS**  
 D. J. Roberts\*<sup>1</sup>, T. Skerry<sup>1</sup>  
<sup>1</sup>Muscular and Skeletal Biology, The University of Sheffield, Sheffield, United Kingdom
- P185-M ASSESSMENT OF PLASTICITY BETWEEN HUMAN MESENCHYMAL STEM CELL-DERIVED OSTEOBLASTS AND ADIPOCYTES BY MICROARRAY ANALYSES AND BIOINFORMATIC EVALUATION**  
 T. Schilling\*<sup>1</sup>, R. Küffner<sup>2</sup>, L. Klein-Hitpass<sup>3</sup>, R. Zimmer<sup>2</sup>, F. Jakob<sup>1</sup>, N. Schütze<sup>1</sup>  
<sup>1</sup>University of Würzburg, Orthopedic Clinic, Orthopedic Center for Musculoskeletal Research, Molecular Orthopedics, Würzburg, <sup>2</sup>Ludwig Maximilians University Munich, Institute of Informatics, Bioinformatics, Munich, <sup>3</sup>University of Duisburg-Essen, Institute of Cell Biology (Tumor Research), Essen, Germany
- P188-M BMP-7, BISPHOSPHONATES AND PTH IN A RAT OPEN FRACTURE MODEL: FUNDAMENTAL DIFFERENCIES IN THEIR EFFECTS ON UNION AND STRENGTH**  
 M. Tagil\*<sup>1</sup>, C. Godfrey<sup>2</sup>, D. Little<sup>2</sup>, M. McDonald<sup>2</sup>, N. Amanat<sup>2</sup>, A. Schindler<sup>2</sup>  
<sup>1</sup>Dep of Orthopedics, Institution of Clinical Sciences, Lund, Sweden, <sup>2</sup>Orthopedic Research Lab, Sydney, Australia
- P191-M THE MECHANOSENSITIVE PART OF A SINGLE OSTEOCYTE, CELL BODY OR CELL PROCESS?**  
 A. Vatsa\*<sup>1</sup>, D. Mizuno<sup>2</sup>, T. H. Smit<sup>3</sup>, C. F. Schmidt<sup>2</sup>, F. C. MacKintosh<sup>2</sup>, J. Klein-Nulend<sup>1</sup>  
<sup>1</sup>Oral Cell Biology, ACTA-UvA and Vrije Universiteit, <sup>2</sup>Physics & Astronomy, Vrije Universiteit, <sup>3</sup>Physics & Medical Technology, VU University Medical Centre, Amsterdam, Netherlands
- P195-M THE UTILITY OF MEASURING TRACP5B TO MONITOR TREATMENT RESPONSE IN CLINICAL CONDITIONS AFFECTING BONE**  
 J. J. Brady\*<sup>1</sup>, B. F. Murray<sup>1</sup>, M. J. McKenna<sup>2</sup>, T. J. McKenna<sup>2</sup>  
<sup>1</sup>Metabolism, <sup>2</sup>Endocrinology, St Vincent's University Hospital, Dublin, Ireland
- P198-M IL6 INHIBITS RANKL-INDUCED OSTEOCLASTOGENESIS BY DIVERTING CELLS INTO THE MACROPHAGE LINEAGE: IMPLICATION OF STAT3**  
 L. Duplomb\*<sup>1</sup>, M. Baud'huin<sup>1</sup>, C. Charrier<sup>1</sup>, V. Trichet<sup>1</sup>, F. Blanchard<sup>1</sup>, D. Heymann<sup>1</sup>  
<sup>1</sup>Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, INSERM ERI7, Nantes, France
- P201-M CHARACTERISATION OF A NOVEL ANTIGEN EXPRESSED IN OSTEOCLASTS AND OSTEOBLASTS**  
 V. J. Green\*<sup>1</sup>, P. M. Wilson<sup>1</sup>, A. A. Walsh<sup>1</sup>, J. A. Gallagher<sup>1</sup>  
<sup>1</sup>Human Anatomy and Cell Biology, University of Liverpool, Liverpool, United Kingdom
- P204-M THE EFFECTS OF VARIOUS GROWTH FACTORS ON HUMAN MESENCHYMAL STEM CELL EXPOSED TO TITANIUM PARTICLES**  
 G. Im\*<sup>1</sup>  
<sup>1</sup>Orthopaedics, Dongguk University International Hospital, Goyang, South Korea
- P207-M A GAMMA-GLUTAMYL PEPTIDE FROM ONION INHIBITS THE DEVELOPMENT AND ACTIVITY OF OSTEOCLASTS IN VITRO**  
 M. Langos\*<sup>1</sup>, W. Hofstetter<sup>1</sup>, S. Dolder<sup>1</sup>, R. Felix<sup>1</sup>, R. C. Mühlbauer<sup>1</sup>, R. Brenneisen<sup>1</sup>  
<sup>1</sup>Department Clinical Research, University of Berne, Berne, Switzerland
- P210-M CALCITONIN PARTLY COUNTERACTS THE SUBCHONDRAL BONE REMODELLING**

**UNDERLYING EXPERIMENTAL OSTEOARTHRITIS: MORPHOMETRIC DATA FROM PQCT SCANNING**

C. Nysse-Behets\*<sup>1</sup>, D. Chappard<sup>2</sup>, J. Devogelaer<sup>3</sup>, D. Manicourt<sup>4</sup>

<sup>1</sup>Experimental Morphology, Université Catholique de Louvain, Brussels, Belgium, <sup>2</sup>INSERM EMI 0335 Remodelage Osseux et Biomatériaux, Université d'Angers, Angers, France, <sup>3</sup>Rheumatology, <sup>4</sup>ICP Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium

**P213-M A NOVEL CYTOKINE FAM3C INDUCES FORMATION OF OSTEOCLAST-LIKE CELLS IN VITRO**

J. Saarimäki<sup>1</sup>, K. G. Buki\*<sup>1</sup>, J. Määttä<sup>1</sup>, P. Rantakari<sup>2</sup>, M. Poutanen<sup>2</sup>, H. K. Väänänen<sup>3</sup>

<sup>1</sup>Department of Anatomy, <sup>2</sup>Department of Physiology, Institute of Biomedicine, University of Turku, <sup>3</sup>Department of Anatomy, Turku, Finland

**P216-M ALTERATION OF CA<sup>2+</sup> SIGNALING AND OSTEOCLAST DIFFERENTIATION IN SERCA2+/- MICE**

K. Shin\*<sup>1</sup>, H. Jo<sup>1</sup>, S. Lee<sup>1</sup>, J. Seo<sup>1</sup>, D. Shin<sup>1</sup>

<sup>1</sup>Oral Biology, Oral Science Research Center, BK21 Project, Yonsei Univ College of Dentistry, Seoul, South Korea

**P219-M ROLE OF THE GEMINAL HYDROXYL GROUP IN TARGET ENZYME INHIBITION BY BISPHTHONATES AND PHOSPHONOCARBOXYLATES**

C. A. Stewart\*<sup>1</sup>, J. E. Dunford<sup>2</sup>, Z. Xia<sup>2</sup>, R. Baron<sup>3</sup>, M. S. Marma<sup>4</sup>, B. A. Kashemirov<sup>4</sup>, C. E. McKenna<sup>4</sup>, F. H. Ebetino<sup>5</sup>, F. P. Coxon<sup>1</sup>

<sup>1</sup>Medicine and Therapeutics, University of Aberdeen, Aberdeen, <sup>2</sup>Botnar Research Centre, University of Oxford, Oxford, <sup>3</sup>Cell and Molecular Biology, Imperial College, London, United Kingdom, <sup>4</sup>Department of Chemistry, University of Southern California, Los Angeles, <sup>5</sup>Procter and Gamble Pharmaceuticals, Cincinnati, United States

**P222-M HYPOXIA INDUCIBLE FACTORS 1 ALPHA AND 2 ALPHA ARE STABILISED IN HUMAN OSTEOCLASTS EXPOSED TO HYPOXIA**

J. C. Utting\*<sup>1</sup>, I. R. Orriss<sup>1</sup>, A. Brandao-Burch<sup>1</sup>, M. L. Key<sup>1</sup>, T. R. Arnett<sup>1</sup>

<sup>1</sup>Anatomy and Developmental Biology, University College London, London, United Kingdom

**P225-M UNIFYING MICRODAMAGE-AND DISUSE-TARGETED RESORPTION: A LACK OF OSTEOCYTIC INHIBITION**

R. F. M. van Oers\*<sup>1</sup>, R. Ruimerman<sup>1</sup>, P. A. J. Hilbers<sup>1</sup>, R. Huiskes<sup>1</sup>

<sup>1</sup>Biomedical Engineering Department, University of Technology Eindhoven, Eindhoven, Netherlands

**P228-M PROGRESSIVE NON-INFECTIOUS ANTERIOR VERTEBRAL FUSION, THE USEFULNESS OF THE CT SCANS TO FURTHER OUR UNDERSTANDINGS**

A. Al Kaissi\*<sup>1</sup>, F. Grill<sup>2</sup>, K. Klaushofer<sup>3</sup>

<sup>1</sup>Osteology, Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital, <sup>2</sup>Orthopaedics, Speising Orthopaedic Hospital, <sup>3</sup>Ludwig Boltzmann Institute of Osteologie, at the Hanusch Hospital, Vienna, Austria

**P231-M CINACALCET AND HYPOCALCIURIC HYPERCALCEMIA WITH RECURRENT PANCREATITIS**

P. Filippini\*<sup>1</sup>, S. Cristallini<sup>1</sup>, G. Policani<sup>1</sup>, A. Nicasi<sup>1</sup>

<sup>1</sup>Ospedale di Umbertide, Centre for Osteoporosis and for Metabolic Bone Diseases, Umbertide, Italy

**P234-M FRIZZLED RELATED PROTEIN-3 VARIANTS AND PATTERNS OF HIP OSTEOARTHRITIS**

A. Gordon<sup>1</sup>, J. Loughlin<sup>2</sup>, L. Southam<sup>2</sup>, A. G. Wilson<sup>3</sup>, G. White<sup>4</sup>, A. Hamer<sup>4</sup>, I. Stockley<sup>4</sup>, R. Eastell<sup>1</sup>, M. Wilkinson\*<sup>4</sup>

<sup>1</sup>Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, <sup>2</sup>Institute of Musculoskeletal Sciences, University of Oxford, Oxford, <sup>3</sup>Division of Genomic Medicine, University of Sheffield, <sup>4</sup>Department of Orthopaedics, The Northern General Hospital, Sheffield, United Kingdom

**P237-M THE ROLE OF VITAMIN D RECEPTOR GENE VARIATION AND ITS INTERACTION WITH IMMUNE REGULATORY MOLECULES IN BONE TURN OVER**

A. Hossein-Nezhad\*<sup>1</sup>, G. Ahangari<sup>2</sup>, Z. Maghbooli<sup>1</sup>, B. Larijani<sup>1</sup>

<sup>1</sup>Endocrinology, Endocrinology and Metabolism Research Center of Tehran University of Medical Sciences, <sup>2</sup>Immunogenetics, National Research Center for Genetic Engineering and Bio Technology, Tehran, Iran (Islamic Republic of)

**P240-M ASSOCIATION OF KIT GENE POLYMORPHISMS WITH BONE MINERAL DENSITY IN POSTMENOPAUSAL KOREAN WOMEN**

J. Koh\*<sup>1</sup>, Y. Chung<sup>2</sup>, J. Lee<sup>3</sup>, H. Kim<sup>4</sup>, B. Oh<sup>5</sup>, K. Kimm<sup>6</sup>, H. Kim<sup>3</sup>, B. Park<sup>7</sup>, H. Shin<sup>7</sup>, E. Park<sup>8</sup>, G. Kim<sup>1</sup>, S. Kim<sup>8</sup>

<sup>1</sup>Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, <sup>2</sup>Department of Internal Medicine, Seoul Veterans Hospital, <sup>3</sup>National Genome Research Institute, National Institute of Health, Seoul, <sup>4</sup>Department of Internal Medicine, Sanbon Medical Center, University of Wonkwang College of Medicine, Iksan, South Korea, <sup>5</sup>National Genome Research Institute, National Institute of Health, Seoul, South Africa, <sup>6</sup>Department of Biochemistry, Eulji University Hospital, Daejeon, <sup>7</sup>Department of Genetic Epidemiology, Snp Genetics, Inc., Seoul, <sup>8</sup>Skeletal Diseases Genome Research Center, Kyungpook National University Hospital, Daegu, South Korea

**P243-M FRACTURE RISK IN MEN UNTIL ADULTHOOD VARIES TWOFOLD DEPENDING ON GC GENOTYPE: RESULTS FROM THE ODENSE ANDROGEN STUDY**

A. L. Lauridsen\*<sup>1</sup>, T. L. Nielsen<sup>2</sup>, M. Andersen<sup>2</sup>, C. Hagen<sup>3</sup>, B. A. Nexø<sup>4</sup>, E. Nexø<sup>1</sup>, K. Brixen<sup>2</sup>

<sup>1</sup>Clinical Biochemistry, Aarhus University Hospital, Aarhus Sygehus, Aarhus, <sup>2</sup>Endocrinology, Odense University Hospital, Odense, <sup>3</sup>Internal Medicine, Copenhagen University Hospital, Gentofte, <sup>4</sup>Institute of Human Genetics, Aarhus University, Aarhus, Denmark

**P246-M ASSOCIATION OF THREE POLYMORPHIC MARKER'S AT THE INTERLEUKIN 6 GENE WITH BONE MINERAL DENSITY IN MEXICAN POPULATION**

J. J. Magaña\*<sup>1</sup>, R. Gomez<sup>2</sup>, B. Cisneros<sup>1</sup>, P. Diez<sup>3</sup>, M. Valdes<sup>2</sup>

<sup>1</sup>Genetics and Molecular Biology, CINVESTAV-IPN, <sup>2</sup>Genetics, <sup>3</sup>Orthopedic Service, National Rehabilitation Institute, Mexico City, Mexico

**P249-M EFFECTS OF PRO12ALA AND C161T POLYMORPHISMS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA GENE ON THE BONE MINERAL METABOLISM IN KOREAN WOMEN**

K. Oh\*<sup>1</sup>, E. Yun<sup>2</sup>, E. Rhee<sup>1</sup>, W. Lee<sup>1</sup>

<sup>1</sup>Endocrinology and Metabolism, Sungkyunkwan University School of Medicine, <sup>2</sup>Radiology, Hallym University, Seoul, South Korea

**P252-M SEQUENCING OF THE PROMOTER REGION AND EXONS 1A AND 1B IN THE HUMAN CALCIUM-SENSING RECEPTOR GENE**

A. Qvist\*<sup>1</sup>, N. R. Jørgensen<sup>2</sup>, P. Schwarz<sup>1</sup>

<sup>1</sup>Research Center of Ageing and Osteoporosis, Department of Geriatrics, County Hospital, Glostrup, <sup>2</sup>Dep. of Clinical Biochemistry, Hvidovre University Hospital, Hvidovre, Denmark

**P255-M MULTI-LOCUS ANALYSIS OF ESTROGEN PATHWAY POLYMORPHISMS AND VERTEBRAL FRACTURE RISK IN ELDERLY WOMEN; AN EXERCISE**

L. Stolk\*<sup>1</sup>, F. Rivadeneira<sup>1</sup>, J. Houwing-Duistermaat<sup>2</sup>, A. Hofman<sup>3</sup>, J. B. J. van Meurs<sup>1</sup>, H. A. P. Pols<sup>1</sup>, A. G. Uitterlinden<sup>1</sup>

<sup>1</sup>Internal Medicine, Erasmus MC, Rotterdam, <sup>2</sup>Medical Statistics, Leiden University Medical Center, Leiden, <sup>3</sup>Epidemiology & Biostatistics, Erasmus MC, Rotterdam, Netherlands

**P259-M THE ASSESSMENT OF BONE TURNOVER IN HYPOTHYROIDIAN MENOPAUSAL WOMEN TREATED WITH DIFFERENT LEVOTHYROXINE DOSES**

E. Circo\*<sup>1</sup>, S. Circo<sup>2</sup>, I. Chirca<sup>3</sup>

<sup>1</sup>Endocrinology, <sup>2</sup>Orthopaedic Surgery, Ovidius University Constanta, Constanta, <sup>3</sup>Infectious Diseases, SCUB, Bucuresti, Romania

**P262-M GH TREATMENT INCREASES CORTICAL THICKNESS IN YOUNG ADULTS WITH CHILDHOOD ONSET GH-DEFICIENCY**

L. Hyldstrup\*<sup>1</sup>

<sup>1</sup>Dept of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark

**P265-M EFFECT OF A SHORT-TERM VITAMIN D TREATMENT ON INFLAMMATORY BIOMARKERS AND OPG/RANKL SYSTEM IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA/OSTEOPOROSIS**

Z. Krivosikova\*<sup>1</sup>, V. Spustova<sup>1</sup>, K. Stefikova<sup>1</sup>, R. Dzurik<sup>1</sup>

<sup>1</sup>Department of Clinical and Experimental Pharmacotherapy, Slovak Medical University, Bratislava, Slovakia

**P268-M CHANGES IN BMD AND CALCITROPIC HORMONS ACCORDING TO LENGTH OF**

## **BREASTFEEDING PERIOD**

U. K. Moeller\*<sup>1</sup>, L. Rejnmark<sup>1</sup>, L. Mosekilde<sup>1</sup>

<sup>1</sup>*Dept. of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus, Denmark*

## **P271-M EVALUATION OF JOINT PATHOLOGY BY MEASURING CARTILAGE DEGRADATION PRODUCTS IN JOINT EXTRACTS**

R. H. Nielsen\*<sup>1</sup>, R. Stoop<sup>2</sup>, D. J. Leeming<sup>3</sup>, P. Qvist<sup>4</sup>, C. Christiansen<sup>5</sup>, L. B. Tanko<sup>6</sup>, M. A. Karsdal<sup>1</sup>

<sup>1</sup>*In Vivo Pharmacology, Nordic Bioscience, Herlev, Denmark*, <sup>2</sup>*NMI, Tübingen University, Reutlingen, Germany*, <sup>3</sup>*Assay Development, Nordic Bioscience A/S*, <sup>4</sup>*Assay Development, Nordic Bioscience, Herlev*, <sup>5</sup>*Clinical Department, CCB, Ballerup*, <sup>6</sup>*In Vivo Pharmacology, Nordic Bioscience A/S, Herlev, Denmark*

## **P274-M DOES TOTAL KNEE REPLACEMENT INFLUENCE THE LEVEL OF INTACT-PARATHYROID HORMONE IN POSTMENOPAUSAL WOMEN SUFFERING FROM END-STAGE KNEE OSTEOARTHRITIS? INTERMEDIATE RESULTS**

K. A. Papavasiliou\*<sup>1</sup>, J. M. Kirkos<sup>1</sup>, R. Zilidou<sup>2</sup>, A. Pavlitou<sup>2</sup>, C. Dimitriou<sup>3</sup>, G. A. Kapetanios<sup>1</sup>

<sup>1</sup>*3rd Orthopaedic Department, Aristotle University of Thessaloniki Medical School*, <sup>2</sup>*Laboratory of Immuno-Chemistry, "Papageorgiou" General Hospital*, <sup>3</sup>*Orthopaedic Department, "Hippokrateion" General Hospital, Thessaloniki, Greece*

## **P277-M VITAMIN D STATUS IN PATIENTS WITH CARDIAC INCOMPENSATION**

L. L. Schierbeck\*<sup>1</sup>, M. F. Hitz<sup>1</sup>, G. B. Jensen<sup>2</sup>, J. L. Madsen<sup>2</sup>, J. B. Jensen<sup>1</sup>

<sup>1</sup>*Calcium and Bone Metabolic Unit*, <sup>2</sup>*Department of Cardiology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark*

## **P280-M BMP-6 PASSES THROUGH THE GASTROINTESTINAL SYSTEM IN NEWBORN RATS**

P. Simic\*<sup>1</sup>, L. Grgurevic<sup>1</sup>, A. Tikvica<sup>1</sup>, I. Erjavec<sup>1</sup>, M. Zuvic<sup>2</sup>, S. Vukicevic<sup>3</sup>

<sup>1</sup>*Department of Anatomy*, <sup>2</sup>*Department of Nuclear Medicine, Medical School*, <sup>3</sup>*Department of Anatomy, Zagreb, Croatia*

## **P283-M CONCENTRATIONS OF CALCIUM, PHOSPHORUS, CARBOXY-TERMINAL TELOPEPTIDES OF TYPE I COLLAGEN AND 1.25 DIHYDROXY VITAMIN D3 AND ACTIVITY OF BONE ALKALINE PHOSPHATASE IN BLOOD SERUM OF PERIPARTURIENT DAIRY COWS**

Z. Stojevic\*<sup>1</sup>, N. Filipovic<sup>1</sup>, V. Kusec<sup>2</sup>, M. Zdelar-Tuk<sup>1</sup>

<sup>1</sup>*Department of Physiology and Radiobiology, Faculty of Veterinary Medicine, University of Zagreb*, <sup>2</sup>*Clinical Hospital Centre Zagreb, Zagreb, Croatia*

## **P286-M FREE TESTOSTERONE AND PHYSICAL ACTIVITY ARE IMPORTANT FOR BONE IN WOMEN AND MEN**

P. Trimpou\*<sup>1</sup>, P. Hansson<sup>2</sup>, G. Lappas<sup>2</sup>, A. Rosengren<sup>2</sup>, L. Wilhelmsen<sup>2</sup>, K. Landin-Wilhelmsen<sup>3</sup>

<sup>1</sup>*Endocrine Section, Dept of Internal Medicine*, <sup>2</sup>*Dept of Internal Medicine*, <sup>3</sup>*Endocrine Section, Sahlgrenska University Hospital, Göteborg, Sweden*

## **P289-M VITAMIN D3 8400 IU ONCE WEEKLY IN ELDERLY SUBJECTS WITH VITAMIN D INSUFFICIENCY: EFFECTS ON SERUM 25-(OH)D LEVEL**

N. Binkley<sup>1</sup>, R. Recker<sup>2</sup>, A. Holst<sup>3</sup>, J. Walliser<sup>4</sup>, P. Lips<sup>5</sup>, M. Pfeifer<sup>6</sup>, K. Krohn<sup>7</sup>, M. Liu<sup>8</sup>, D. Cohn<sup>8</sup>, L. E. Wehren\*<sup>9</sup>, D. Papanicolaou<sup>8</sup>

<sup>1</sup>*University of Wisconsin, Madison, WI*, <sup>2</sup>*Creighton University, Omaha, NE, United States*, <sup>3</sup>*Clinical Research Hamburg, Hamburg, Germany*, <sup>4</sup>*Hospital Angeles del Pedregal, Mexico City, Mexico*, <sup>5</sup>*Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands*, <sup>6</sup>*Klinik der Furstenhof, Bad Pyrmont, Germany*, <sup>7</sup>*MCR Rheumatology Associates, Pittsburgh, PA*, <sup>8</sup>*Merck Research Laboratories, Rahway, NJ*, <sup>9</sup>*Medical Communications, Merck Research Laboratories, Rahway, United States*

## **P292-M DRUG THERAPY UTILIZATION IMPROVES IN PATIENTS WITH SEVERE FOLLOWING A MULTIFACETED OSTEOPOROSIS EDUCATIONAL INTERVENTION: CANADIAN QUALITY CIRCLE (CQC) PILOT PROJECT**

J. D. Adachi\*<sup>1</sup>, G. Ioannidis<sup>1</sup>, A. Hodsman<sup>2</sup>, L. Thabane<sup>3</sup>, A. Papaioannou<sup>1</sup>, A. Gafni<sup>3</sup>, B. Kvern<sup>4</sup>, D. Johnstone<sup>5</sup>, C. Crowley<sup>6</sup>

<sup>1</sup>*Medicine, McMaster University, Hamilton*, <sup>2</sup>*Medicine, University of Western Ontario, London*, <sup>3</sup>*Clinical Epidemiology and Biostatistics, McMaster University, Hamilton*, <sup>4</sup>*Medicine, University of Manitoba, Winnipeg*, <sup>5</sup>*National Professional Relations*, <sup>6</sup>*Medical and Technical Affairs, P&G Pharmaceuticals, Toronto, Canada*

## **P295-M POST-MENOPAUSAL OSTEOPOROSIS PATIENTS' PREFERENCES FOR ADMINISTRATION**

## **OF PARATHYROID HORMONE TREATMENT**

M. Asmussen\*<sup>1</sup>, L. H. Hyldstrup<sup>2</sup>

<sup>1</sup>Health Economics, <sup>2</sup>Medical Department, Nycomed, Roskilde, Denmark

## **P298-M DIGITAL X-RAY RADIOGRAMMETRY: COMPARISON OF MEASUREMENT IN THE DOMINANT AND THE NON-DOMINANT HAND. RESULTS FROM THE COPENHAGEN CITY HEART STUDY**

P. Bach-Mortensen\*<sup>1</sup>, L. Hyldstrup<sup>1</sup>, M. Appleyard<sup>2</sup>, K. Hindsoe<sup>3</sup>, P. Gebuhr<sup>2</sup>, S. Sonne-Holm<sup>3</sup>

<sup>1</sup>Dept. of Endocrinology, Hvidovre University Hospital, Hvidovre, <sup>2</sup>Copenhagen City Heart Study, Bispebjerg University Hospital, Copenhagen, <sup>3</sup>Dept. of Orthopaedic Surgery, Hvidovre University Hospital, Hvidovre, Denmark

## **P301-M DOES AN OSTEOPOROSIS AND FALLS CASE-FINDING PROGRAMME IN A UK PRIMARY CARE SETTING LEAD TO LASTING IMPROVEMENTS IN MEASURED STANDARDS OF CARE WHEN COMPARED TO USUAL PRACTICE?**

J. R. Bayly\*<sup>1</sup>, R. D. Hollands<sup>2</sup>, S. J. Yemm<sup>3</sup>, S. E. Riordan-Jones<sup>3</sup>, I. Brough-Williams<sup>3</sup>, M. Thatcher<sup>3</sup>, R. E. Clifford<sup>3</sup>

<sup>1</sup>Faculty of Education, Health and Sciences, University of Derby, Derby, <sup>2</sup>Underwood Surgery, Gloucestershire Primary Care Trust, Cheltenham, <sup>3</sup>Gloucestershire Primary and Community Care Audit Group, Gloucestershire Primary Care Trust, Gloucester, United Kingdom

## **P304-M USE OF GENOMIC PROFILING FOR UNDERSTANDING THE BISPHOSPHONATES MODE OF ACTION AT THE MOLECULAR LEVEL**

N. Bivi\*<sup>1</sup>, R. Harrison<sup>2</sup>, M. Romanello<sup>1</sup>, F. Brancia<sup>3</sup>, F. Quadrifoglio<sup>1</sup>, L. Moro<sup>4</sup>, G. Tell<sup>1</sup>, D. Delneri<sup>2</sup>

<sup>1</sup>Department of Biomedical Sciences and Technologies, University of Udine, Udine, Italy, <sup>2</sup>Faculty of Life Sciences, University of Manchester, <sup>3</sup>Shimadzu Research Laboratory (Europe), Manchester, Manchester, United Kingdom, <sup>4</sup>Department of Biochemistry, Centre for the Study of Metabolic Bone Diseases, University of Trieste, Trieste, Italy

## **P307-M ALENDRONATE WITH OR WITHOUT CALCIUM SUPPLEMENTATION WAS SIGNIFICANTLY MORE EFFECTIVE THAN CALCIUM SUPPLEMENTATION ALONE IN IMPROVEMENT OF BONE MINERAL DENSITY AND BONE TURNOVER MARKERS, WITH NO DIFFERENCE IN UPPER-GI TOLERABILITY**

S. Bonnick\*<sup>1</sup>, S. Broy<sup>2</sup>, F. Kaiser<sup>3</sup>, C. Teutsch<sup>4</sup>, E. Rosenberg<sup>5</sup>, P. DeLuca<sup>6</sup>, M. Melton<sup>7</sup>

<sup>1</sup>Medicine, CRC of North Texas, Denton, <sup>2</sup>Rheumatology, Illinois Bone and Joint Institute, Morton Grove, <sup>3</sup>Regional Medical Directors, <sup>4</sup>Medical Services, <sup>5</sup>Clinical Development, <sup>6</sup>Biostatistics, <sup>7</sup>Medical Products, Merck & Co., Inc., West Point, United States

## **P310-M BONE TURNOVER MARKER REDUCTIONS AFTER 24 MONTHS OF TREATMENT WITH RISEDRONATE: RESULTS FROM THE RISEDRONATE MALE OSTEOPOROSIS STUDY**

S. Boonen\*<sup>1</sup>, P. Garnero<sup>2</sup>, C. Y. Guo<sup>3</sup>, R. Eusebio<sup>3</sup>, P. D. Delmas<sup>4</sup>

<sup>1</sup>Center for Metabolic Bone Disease, Division of Geriatric Medicine, Leuven, Belgium, <sup>2</sup>INSERM, Molecular Markers, Lyon, France, <sup>3</sup>Procter & Gamble Pharmaceuticals, Mason, OH, United States, <sup>4</sup>INSERM, Research Unit 403, Lyon, France

## **P313-M STRONTIUM RANELATE EFFECTS ON OSTEOBLASTIC DIFFERENTIATION ARE ASSOCIATED WITH PGE2-DEPENDENT GROWTH FACTOR PRODUCTION**

S. Choudhary\*<sup>1</sup>, P. Halbout<sup>2</sup>, C. Alander<sup>1</sup>, L. Raisz<sup>1</sup>, C. Pilbeam<sup>1</sup>

<sup>1</sup>Musculoskeletal Institute, University of Connecticut Health Center, Farmington, United States, <sup>2</sup>Rheumatology Department, Institut de Recherches Internationales Servier, Courbevoie, France

## **P316-M PROGRESSIVE EFFICACY IMPROVEMENTS WITH QUARTERLY INTRAVENOUS IBANDRONATE INJECTIONS: THE DIVA STUDY LONG TERM EXTENSION**

E. Czerwinski\*<sup>1</sup>, B. Langdahl<sup>2</sup>, J. Stepan<sup>3</sup>, R. Grant<sup>4</sup>, C. Neate<sup>5</sup>, G. Bianchi<sup>6</sup>

<sup>1</sup>Department of Medicine, Krakow Medical Centre, Krakow, Poland, <sup>2</sup>Endocrinology and Metabolism, Aarhus University Hospital, Aarhus, Denmark, <sup>3</sup>Department of Internal Medicine, Charles University, Prague, Czech Republic, <sup>4</sup>Inflammatory and Bone Diseases, Hoffmann-La Roche Inc., Nutley, United States, <sup>5</sup>Pharma-Development Medical Biostatistics, Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>6</sup>Divisione di Rheumatologia, Ospedale La Colletta, Genovese, Italy

## **P319-M EFFECTS OF IBANDRONATE, DAILY OR MONTHLY ADMINISTERED, ON BONE QUALITY AND REMODELLING IN ORCHIDECTOMIZED RATS**

I. Quiroga<sup>1</sup>, M. Montero<sup>2</sup>, S. Dapia<sup>3</sup>, J. Caeiro<sup>3</sup>, J. Moreno-Rubio<sup>4</sup>, M. Diaz-Curiel<sup>5</sup>, S. Gomez<sup>6</sup>, C. De la Piedra\*<sup>2</sup>

<sup>1</sup>Endocrinology, Hospital Puerta de Hierro, <sup>2</sup>Biochemistry, Osteoarticular Pathology Laboratory, Fundacion Jimenez Diaz, Madrid, <sup>3</sup>Project Coordination, Novaria I+D, Ourense, <sup>4</sup>Reumatology, Osteoarticular Pathology Laboratory, <sup>5</sup>Internal Medicine, Fundacion Jimenez Diaz, Madrid, <sup>6</sup>Anatomopathology, Universidad de Cadiz, Cadiz, Spain

**P322-M 3D FEMUR GEOMETRY FROM 2D DXA SCANS: BONE VOLUME ESTIMATION**

L. del Rio<sup>1</sup>, R. Vila<sup>1</sup>, L. del Rio (Jr)<sup>1</sup>, J. Pascual<sup>1</sup>, S. Di Gregorio\*<sup>1</sup>, C. Solé<sup>1</sup>, M. Garcia<sup>1</sup>, J. Rosales<sup>1</sup>

<sup>1</sup>Densitometry, Unit, Barcelona, Spain

**P325-M FOREARM BMD AND AGE, NOT FALLS OR PREVIOUS FRACTURE IDENTIFIES FRACTURE RISK**

M. N. Dugard<sup>1</sup>, T. Jones<sup>1</sup>, K. Penry<sup>1</sup>, T. D. Ryan<sup>1</sup>, H. C. Williams<sup>1</sup>, M. W. J. Davie\*<sup>1</sup>

<sup>1</sup>Charles Salt Research Centre, RJ and AH Orthopaedic Hospital, Oswestry, United Kingdom

**P328-M SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES-AN INTERDISCIPLINARY PILOT PROJECT IN HANUSCH-HOSPITAL, VIENNA (PARTIAL RESULTS)**

H. Eichbauer\*<sup>1</sup>, E. Zwettler<sup>1</sup>, W. Scharf<sup>2</sup>, K. Klaushofer<sup>1</sup>

<sup>1</sup>4<sup>th</sup> Medical Department, <sup>2</sup>Accident Ward, Hanusch-Hospital, Vienna, Austria

**P331-M CO-PRESCRIPTION OF CALCIUM &/OR VITAMIN D WITH ONCE WEEKLY BISPHOSPHONATE THERAPY: FINDINGS FROM A FRENCH LONGITUDINAL PATIENT DATABASE**

P. Fardellone\*<sup>1</sup>, B. Mann<sup>2</sup>

<sup>1</sup>Department of Rheumatology, CHU, Amiens, France, <sup>2</sup>, Procter & Gamble Pharmaceuticals, Schwalbach, Germany

**P334-M PREDICTING VERTEBRAL FRACTURES: SMALL VERTEBRAL DEFORMITIES INCREASE THE RISK OF SUBSEQUENT VERTEBRAL FRACTURE AT ONE YEAR – EARLY AND EFFECTIVE FRACTURE RISK REDUCTION WITH RISEDRONATE**

D. Felsenberg\*<sup>1</sup>, C. Recknor<sup>2</sup>, X. Zhou<sup>3</sup>, A. Grauer<sup>3</sup>

<sup>1</sup>Muscle and Bone Research Centre, Freie and Humboldt University Berlin, Berlin, Germany, <sup>2</sup>, United Osteoporosis Center, Gainesville, GA, <sup>3</sup>, Procter & Gamble Pharmaceuticals, Mason, OH, United States

**P337-M EFFECT OF PROPRANOLOL ON THE GLUCOCORTICOID-INDUCED BONE CHANGES IN YOUNG RATS**

J. Folwarczna\*<sup>1</sup>, L. Sliwinski<sup>1</sup>, M. Kulik<sup>1</sup>, B. Nowinska<sup>1</sup>, U. Cegiela<sup>1</sup>, M. Pytlik<sup>1</sup>, I. Kaczmarczyk-Sedlak<sup>1</sup>, H. I. Trzeciak<sup>1</sup>

<sup>1</sup>Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

**P340-M CIRCULATING OSTEOCLAST PRECURSOR CELL POPULATIONS AND THEIR CYTOKINE RECEPTORS ARE NOT TARGETS FOR ALENDRONATE ACTION IN POSTMENOPAUSAL OSTEOPOROSIS**

S. J. Glover\*<sup>1</sup>, R. Eastell<sup>1</sup>, A. Rogers<sup>1</sup>

<sup>1</sup>Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom

**P343-M EFFECT OF FULL-LENGTH PARATHYROID HORMONE PTH(1-84) IN REDUCING NEW VERTEBRAL FRACTURES IN OSTEOPOROSIS PATIENTS WITH AND WITHOUT A MATERNAL HISTORY OF OSTEOPOROSIS**

C. Gómez Alonso\*<sup>1</sup>, M. Rodríguez-García<sup>2</sup>, H. Greisen<sup>3</sup>

<sup>1</sup>Internal Medicine Dept., Hospital Central de Asturias, <sup>2</sup>Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación, Oviedo, Spain, <sup>3</sup>International Medical Affairs, Nycomed, Roskilde, Denmark

**P346-M KYPHOPLASTY PERSISTENTLY REDUCES PAIN IN PATIENTS WITH OSTEOPOROTIC VERTEBRAL FRACTURES-3 YEAR OUTCOME OF A PROSPECTIVE CONTROLLED COHORT STUDY**

C. Kasperk\*<sup>1</sup>, K. Da Fonseca<sup>2</sup>, J. Hillmeier<sup>2</sup>, P. Meeder<sup>2</sup>, M. Libicher<sup>3</sup>, G. Nöldge<sup>3</sup>, U. Sommer<sup>1</sup>, U. Hilscher<sup>1</sup>, P. Nawroth<sup>1</sup>, I. A. Grafe<sup>1</sup>

<sup>1</sup>Internal Medicine I, <sup>2</sup>Department of Surgery, <sup>3</sup>Department of Radiology, University of Heidelberg, Heidelberg, Germany

**P349-M SERUM SRANKL LEVELS IN OSTEOPOROTIC PATIENTS USING A SIGNAL AMPLIFIED**

## ELISA

G. Hawa\*<sup>1</sup>, B. Lindner<sup>1</sup>, J. Marc<sup>2</sup>

<sup>1</sup>Research and Development, Biomedica Gruppe, Vienna, Austria, <sup>2</sup>Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

### **P352-M STRONTIUM RANELATE AND CALCIUM EXERT CUMULATIVE EFFECTS ON OSTEOCLASTS BY ACTIVATION OF DIFFERENT INTRACELLULAR SIGNALING PATHWAYS, DOWNSTREAM THE CALCIUM-SENSING RECEPTOR**

A. S. Hurtel<sup>1</sup>, R. Mentaverri\*<sup>1</sup>, A. Wattel<sup>1</sup>, S. Kamel<sup>1</sup>, M. Brazier<sup>1</sup>

<sup>1</sup>Unité de Recherches sur les Mécanismes de la Résorption Osseuse, INSERM, Amiens, France

### **P355-M NO INFLUENCE OF PREVIOUS BIPHOSPHONATE TREATMENT ON TERIAPRATIDE RESPONSE. THE DANISH PTH DATABASE**

L. Hyldstrup<sup>1</sup>, B. Langdahl\*<sup>2</sup>, J. B. Jensen<sup>1</sup>, K. Brixen<sup>3</sup>, P. Eiken<sup>4</sup>, P. Schwarz<sup>5</sup>, A. Schmitz<sup>6</sup>, H. Rønne<sup>7</sup>, H. K. Brockstedt<sup>8</sup>

<sup>1</sup>Dept of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, <sup>2</sup>Dept. of Endocrinology, Aarhus Sygehus, University of Aarhus, Aarhus, <sup>3</sup>Dept. of Endocrinology, Odense University Hospital, Odense, <sup>4</sup>Internal Medicine, Hillerød Sygehus, Hillerød, <sup>5</sup>Dept. of Geriatrics, Glostrup Hospital, University of Copenhagen, Glostrup, <sup>6</sup>Internal Medicine, Vejle Sygehus, Vejle, <sup>7</sup>Internal Medicine, Farsø Sygehus, Farsø, <sup>8</sup>Internal Medicine, Silkeborg Centralsygehus, Silkeborg, Denmark

### **P358-M COMPERATIVE STUDY BETWEEN HISTOLOGICAL AND RADIOLOGICAL METHODS IN THE DIAGNOSIS OF INVOLUTIONAL OSTEOPOROSIS IN PATIENTS WITH FRACTURE NECK FEMUR**

A. H. Jasim<sup>1</sup>, A. H. Jasim\*<sup>1</sup>

<sup>1</sup>Orthopaedic Department, Surgical Specialization Teaching Hospital, Baghdad, Iraq

### **P361-M COMPARISON OF CHANGES IN BONE MINERAL DENSITY AND BONE TURNOVER MARKER WITH ALENDRONATE ONCE-WEEKLY AND BI-WEEKLY IN POSTMENOPAUSAL KOREAN WOMEN**

H. Oh\*<sup>1</sup>, I. Joo<sup>1</sup>, B. Yu<sup>2</sup>, K. Kim<sup>3</sup>

<sup>1</sup>Family Medicine, Cheilgeneral Hospital, Seoul, <sup>2</sup>Family Medicine, Kunyang University, Taejeon, <sup>3</sup>Family Medicine, Catholic University, Seoul, South Korea

### **P364-M EFFICACY OF HIGH DOSE BLACK COHOSH**

B. M. Kang\*<sup>1</sup>, S. Lee<sup>1</sup>, Y. Goo<sup>1</sup>, S. Kim<sup>1</sup>, H. Chae<sup>1</sup>, C. Kim<sup>1</sup>

<sup>1</sup>Obstetrics and Gynecology, Asan Medical Center, Seoul, South Korea

### **P367-M CHANGES IN SERUM CTX AFTER 5 YEARS RISEDRONATE TREATMENT IN POSTMENOPAUSAL GREEK WOMEN**

I. C. H. Koulouris\*<sup>1</sup>, G. Skarantavos<sup>1</sup>, P. Katsimbri<sup>1</sup>, T. Kaplanoglou<sup>2</sup>, E. Metania<sup>1</sup>, E. Konstantellou<sup>3</sup>, S. N. Panagiotis<sup>1</sup>

<sup>1</sup>University Orthopaedic Clinic of Athens, Greece, Attikon University Hospital of Athens, Athens, <sup>2</sup>University Orthopaedic Clinic of Athens, Greece, Attikon University Hospital of Athens, Athens, <sup>3</sup>Biochemistry, Ag. Panteleimon General Hospital of Pireus, Athens, Greece

### **P370-M DAILY ORAL AND INTERMITTENT INTRAVENOUS IBANDRONATE HAVE SIMILAR BONE SAFETY PROFILES**

B. Langdahl\*<sup>1</sup>, L. Ste-Marie<sup>2</sup>, I. Jonkanski<sup>3</sup>, C. Neate<sup>4</sup>, R. R. Recker<sup>5</sup>

<sup>1</sup>Endocrinology and Metabolism, Aarhus University Hospital, Aarhus C, Denmark, <sup>2</sup>University of Montreal, Centre de Recherche du CHUM, Hôpital Saint-Luc, Montreal, Canada, <sup>3</sup>Department of Medical Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland, <sup>4</sup>Pharma-Development Medical Biostatistics, Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>5</sup>Osteoporosis Research Center, Creighton University, Omaha, United States

### **P373-M ASSOCIATION BETWEEN BIOCHEMICAL MARKERS OF BONE TURNOVER AND TOTAL SKELETAL UPTAKE OF TECHNETIUM-99M LABELED METHYLENE DIPHOSPHONATE**

J. Lenora\*<sup>1</sup>, K. Norrgren<sup>2</sup>, O. Thorsson<sup>2</sup>, P. Wollmer<sup>2</sup>, K. J. Obrant<sup>1</sup>, K. K. Ivaska<sup>1</sup>

<sup>1</sup>Department of Orthopaedics, <sup>2</sup>Department of Clinical Physiology, Lund University, Malmö, Sweden

### **P376-M EFFECTS OF PRIOR ANTIRESORPTIVE THERAPY ON MARKERS OF BONE FORMATION AFTER 6 MONTHS OF TERIPARATIDE TREATMENT IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM THE EUROFORS TRIAL**

G. B. Obermaier-Pietsch\*<sup>1</sup>, F. Marin<sup>2</sup>, E. V. McCloskey<sup>3</sup>, P. Hadji<sup>4</sup>, M. E. Simoes<sup>5</sup>, C. Barker<sup>2</sup>, H. Oertel<sup>6</sup>, T. N. Nickelsen<sup>6</sup>, S. Boonen<sup>7</sup>

<sup>1</sup>Universitätsklinik für Innere Medizin, Med. Universität, Graz, Austria, <sup>2</sup>Medical Research, Lilly Research Center, Windlesham, <sup>3</sup>Academic Unit Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, <sup>4</sup>Endocrinology, Universitaets-Frauenklinik, Marburg, Germany, <sup>5</sup>Reumatologia, Inst. Portugues Reumatologia, Lisbon, Portugal, <sup>6</sup>Medical Research, Lilly, Bad Homburg, Germany, <sup>7</sup>Geriatric Medicine, Universitaire Ziekenhuizeb, Leuven, Belgium

**P379-M IMPACT OF BISPHOSPHONATE WASH-OUT PRIOR TO TERIPARATIDE THERAPY IN CLINICAL PRACTICE**

C. Meier\*<sup>1</sup>, C. Keel<sup>1</sup>, C. A. Kraenzlin<sup>1</sup>, B. Mueller<sup>1</sup>, M. E. Kraenzlin<sup>1</sup>

<sup>1</sup>Division of Endocrinology, University Hospital, Basel, Switzerland

**P382-M USES OF TOPICAL BISPHOSPHONATES IN DENTAL PRACTICE. A PRELIMINARY REPORT ON COAGULATION**

V. Montangero\*<sup>1</sup>, A. Espósito<sup>2</sup>, E. J. Roldán<sup>3</sup>

<sup>1</sup>Osteology, Univ. Maimónides, Buenos Aires, Argentina, <sup>2</sup>Osteology, Univ. Maimónides, Buenos Aires, Spain,

<sup>3</sup>Scientific Direction, Gador S.A., Bs. As., Argentina

**P385-M PRIMARY- AND SECONDARY PROPHYLAXIS TO THE USE OF INHALED GLUCOCORTICOID IN PRIMARY HEALTH CARE**

B. R. Nielsen\*<sup>1</sup>, N. R. Jørgensen<sup>2</sup>, P. Schwarz<sup>1</sup>

<sup>1</sup>Research Centre of Ageing and Osteoporosis, Department of Geriatrics, Glostrup University Hospital, Glostrup, <sup>2</sup>Department of Clinical Biochemistry, Hvidovre University Hospital, Hvidovre, Denmark

**P388-M PRIMARY CARE PHYSICIANS' PERCEIVED CERTAINTY OF THEIR PATIENTS RISK FACTOR STATUS INCREASES FOLLOWING A MULTIFACETED OSTEOPOROSIS EDUCATIONAL INTERVENTION: CANADIAN QUALITY CIRCLE (CQC) NATIONAL PROJECT**

A. Papaioannou\*<sup>1</sup>, G. Ioannidis<sup>1</sup>, A. Hodsmann<sup>2</sup>, B. Kvern<sup>3</sup>, L. Thabane<sup>4</sup>, A. Gafni<sup>4</sup>, D. Johnstone<sup>5</sup>, C. Crowley<sup>6</sup>, J. D. Adachi<sup>1</sup>

<sup>1</sup>Medicine, McMaster University, Hamilton, <sup>2</sup>Medicine, University of Western Ontario, London, <sup>3</sup>Medicine, University of Manitoba, Winnipeg, <sup>4</sup>Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, <sup>5</sup>National Professional Relations, <sup>6</sup>Medical and Technical Affairs, P&G Pharmaceuticals, Toronto, Canada

**P391-M ATORVASTATIN AND BONE MASS**

J. L. Pérez-Castrillón\*<sup>1</sup>, L. Abad<sup>1</sup>, G. Vega<sup>1</sup>, A. Sanz-Cantalapiedra<sup>1</sup>, M. García-Porrero<sup>1</sup>, A. Dueñas-Laita<sup>1</sup>

<sup>1</sup>Internal Medicine, University Hospital Rio Hortega, Valladolid, Spain

**P394-M SHORT-TERM EFFICACY OF ALENDRONATE IN WHEEL-CHAIR BOUND PATIENTS**

W. Pluskiewicz\*<sup>1</sup>, P. Adamczyk<sup>2</sup>, P. Sawaryn<sup>3</sup>, B. Drozdowska<sup>4</sup>

<sup>1</sup>Dept. and Clinic of Internal Diseases, Diabetology and Nephrology, Metabolic Bone Diseases Unit, <sup>2</sup>Department and Clinic of Pediatrics, Pediatric Nephrology and Endocrinology, Silesian School of Medicine, Zabrze, <sup>3</sup>Nursing Home for Disabled Subjects, Silesian School of Medicine, Miko<sup>3</sup>ów, <sup>4</sup>Department and Chair of Pathomorphology, Silesian School of Medicine, Zabrze, Poland

**P397-M LOW USAGE OF CALCIUM AND VITAMIN D WITH BISPHOSPHONATE THERAPY IN POST-MENOPAUSAL OSTEOPOROTIC WOMEN IN FRANCE AND IN SPAIN**

J. M. Quesada\*<sup>1</sup>, B. Mann<sup>2</sup>

<sup>1</sup>Unidad de Metabolismo Mineral, Hospital Universitario Reina Sofía, Cordoba, Spain, <sup>2</sup>Procter & Gamble Pharmaceuticals, Schwalbach, Germany

**P400-M THE MOBILE STUDY LONG-TERM EXTENSION: PROGRESSIVE IMPROVEMENTS IN EFFICACY WITH ORAL IBANDRONATE (150MG) WHEN ADMINISTERED MONTHLY**

J. Y. Reginster\*<sup>1</sup>, C. Cooper<sup>2</sup>, F. Sedarati<sup>3</sup>, C. Neate<sup>4</sup>, J. A. Stakkestad<sup>5</sup>

<sup>1</sup>Dept of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, <sup>2</sup>MRC Epidemiology Resource Centre, University of Southampton, Southampton, <sup>3</sup>Inflammatory and Bone Diseases, Hoffmann-La Roche Inc., Nutley, United States, <sup>4</sup>Pharma-Development Medical Biostatistics, Roche Products Ltd, Welwyn Garden City, United Kingdom, <sup>5</sup>Department of Medicine, CECOR AS, Haugesund, Norway

**P403-M CHANGES IN SERUM CATHEPSIN K LEVELS, CTX AND BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN TREATED WITH ALENDRONATE**

R. Reyes-García\*<sup>1</sup>, D. Fernández-García<sup>1</sup>, A. Sebastián Ochoa<sup>1</sup>, P. Mezquita-Raya<sup>1</sup>, P. Rozas Moreno<sup>1</sup>, M. E. Muñoz-Torres<sup>1</sup>

<sup>1</sup>Bone Metabolic Unit, Endocrinology Division, San Cecilio University Hospital, Granada, Spain

**P406-M SHORT TERM ORAL PAMIDRONATE IMPROVES OSTEOPENIC SITES AT THE HUMAN MANDIBLE. A PQCT DENSITOMETRIC ANALYSIS**

V. E. Montangero\*<sup>1</sup>, E. J. A. Roldan<sup>2</sup>

<sup>1</sup>Osteology, Maimónides University, <sup>2</sup>Scientific Direction, Gador SA, Buenos Aires, Argentina

**P409-M REDUCTION IN BONE TURNOVER RESULTS IN A TRANSIENT HIGHLY UNIFORM MINERALIZATION STATE**

D. Ruffoni\*<sup>1</sup>, P. Fratzl<sup>1</sup>, P. Roschger<sup>2</sup>, K. Klaushofer<sup>2</sup>, R. Weinkamer<sup>1</sup>

<sup>1</sup>Department of Biomaterials, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, <sup>2</sup>Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK and AUVA Trauma Center Meidling, <sup>4</sup>th Med. Dep. Hanusch Hospital, Vienna, Austria

**P412-M ACCURATE DETECTION OF ABDOMINAL AORTIC CALCIFICATION ON LATERAL SPINE DXA (VFA) IMAGES**

J. T. Schousboe\*<sup>1</sup>, K. E. Wilson<sup>2</sup>, T. N. Hangartner<sup>3</sup>

<sup>1</sup>Rheumatology, Park Nicollet Health Services, Minneapolis, <sup>2</sup>Senior Scientist, Hologic, Inc, Bedford, MA, <sup>3</sup>Biomedical Imaging Laboratory, Wright State University, Dayton, OH, United States

**P415-M THE EFFECTS OF ESTROGEN RECEPTORS AND AROMATASE GENE POLYMORPHISMS ON BONE MINERAL DENSITY, LIPID PROFILE AND THE RESPONSE TO HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN**

S. Silvestri\*<sup>1</sup>, A. Gozzini<sup>1</sup>, C. Christiansen<sup>2</sup>, M. Brandi<sup>1</sup>

<sup>1</sup>Department of Internal Medicine, University of Florence, Florence, Italy, <sup>2</sup>Center for Clinical and Basic Research, Center for Clinical and Basic Research, Ballerup, Denmark

**P418-M COMPARISON OF EFFECTS OF GENISTEIN, RALOXIFENE AND ESTRADIOL ON DEVELOPMENT OF OVARECTOMY-INDUCED OSTEOPENIA IN RATS IN VIVO AND ON MURINE OSTEOBLAST ACTIVITY IN VITRO**

L. Sliwinski<sup>1</sup>, J. Folwarczna\*<sup>1</sup>, E. Jakubiak<sup>1</sup>, A. Wywiol<sup>1</sup>, U. Cegiela<sup>1</sup>, B. Nowinska<sup>1</sup>, M. Pytlik<sup>1</sup>, I. Kaczmarczyk-Sedlak<sup>1</sup>, H. I. Trzeciak<sup>1</sup>

<sup>1</sup>Department of Pharmacology, Medical University of Silesia, Sosnowiec, Poland

**P421-M SELF-REFERRAL FOR OSTEOPOROSIS ASSESSMENT WITH DXA – WHAT IS THE DIFFERENCE TO PATIENTS SENT BY THEIR PHYSICIAN?**

J. Swanenburg<sup>1</sup>, D. Uebelhart\*<sup>2</sup>, M. Di chiara<sup>1</sup>, G. W. Goerres<sup>3</sup>

<sup>1</sup>Department of Rheumatology and Institute of Physical Medicine, <sup>2</sup>Centre for Prevention and Treatment of Osteoporosis, <sup>3</sup>Department of Medical Radiology, University Hospital Zurich, Zurich, Switzerland

**P424-M PRECISION EVALUATION OF LUNAR IDXA BODY COMPOSITION MEASUREMENTS**

E. Toussiro\*<sup>1</sup>, F. Penfornis<sup>2</sup>, D. Wendling<sup>1</sup>

<sup>1</sup>Department of Rheumatology, <sup>2</sup>Department of Endocrinology, University Hospital Jean Minjoz, Besançon, France

**P427-M EFFECTS OF STRONTIUM RANELATE ON BONE MINERAL DENSITY AND FRACTURE RISK – A META-ANALYSIS**

P. Vestergaard\*<sup>1</sup>, N. Rye Jørgensen<sup>2</sup>, L. Mosekilde<sup>3</sup>, P. Schwarz<sup>4</sup>

<sup>1</sup>The Osteoporosis Clinic, Aarhus Amtssygehus, Aarhus, <sup>2</sup>Department of Clinical Biochemistry, Hvidovre Hospital, Copenhagen, <sup>3</sup>Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus, <sup>4</sup>Research Center of Aging and Osteoporosis, Department of Geriatrics, Glostrup University Hospital, Copenhagen, Denmark

**P430-M VITAMIN D RECEPTOR (VDR) GENE FOKI POLYMORPHISM AS INDICATOR OF ALENDRONATE THERAPY EFFECTIVENESS**

A. Wawrzyniak\*<sup>1</sup>, W. Horst Sikorska<sup>1</sup>, R. Slomski<sup>1</sup>

<sup>1</sup>Poznan University of Medical Sciences, Department of Family Medicine, Poznan, Poland

**P433-M BONE EFFECTS OF CATHEPSIN K INHIBITORS IN THE GROWING RABBIT**

B. Pennypacker<sup>1</sup>, S. Rodan<sup>1</sup>, G. Rodan<sup>1</sup>, C. Black<sup>1</sup>, R. Oballa<sup>1</sup>, L. E. Wehren\*<sup>2</sup>, D. Kimmel<sup>1</sup>

<sup>1</sup>, Merck Research Laboratories, West Point, PA, <sup>2</sup>Medical Communications, Merck Research Laboratories, Rahway, United States

- P436-M THE EFFECT OF HEPATIC OR RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF PTH (1-84)**  
D. S. Wells\*<sup>1</sup>  
<sup>1</sup>*Medical Department, NPS Pharmaceuticals, Parsippany, United States*
- P439-M PREDICTING THE CLINICAL POTENCIES OF BISPHOSPHONATES: DIVERGENCE OF HYDROXYAPATITE AND FARNESYL DIPHOSPHATE SYNTHASE BINDING AFFINITIES**  
Z. XIA\*<sup>1</sup>, J. Dunford<sup>1</sup>, M. A. Lawson<sup>1</sup>, J. T. Triffitt<sup>1</sup>, B. L. Barnett<sup>2</sup>, F. H. Ebetino<sup>2</sup>, R. G. G. Russell<sup>1</sup>  
<sup>1</sup>*Nuffield Department of Orthopaedic Surgery, Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom*, <sup>2</sup>*New Drug Development, Procter and Gamble Pharmaceuticals, Mason, Ohio, United States*
- P442-M BONE MINERAL DENSITY IN MALE RATS WITH DIET INDUCED LIVER IMPAIRMENT**  
P. Zivny\*<sup>1</sup>, H. Zivna<sup>2</sup>, P. Hrubá<sup>1</sup>, L. Pavlikova<sup>1</sup>  
<sup>1</sup>*Institute of Clinical Biochemistry and Diagnostics*, <sup>2</sup>*Radioisotope Laboratories and Vivarium, University Hospital, Charles University, Hradec Kralove, Czech Republic*
- P444-M PREVALANCE OF BONE MINERALIZATION DEFECTS IN GERMANY: A HISTOMORPHOMETRIC ANALYSIS AFTER THE INCLUSION OF 440 PATIENTS**  
M. Priemel\*<sup>1</sup>, J. Schlie<sup>1</sup>, C. Von Domarus<sup>1</sup>, S. Kessler<sup>1</sup>, T. O. Klädde<sup>1</sup>, K. Püschel<sup>2</sup>, M. Amling<sup>1</sup>  
<sup>1</sup>*Center for Biomechanics and Skeletal Biology*, <sup>2</sup>*Department of Forensic Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany*
- P447-M SCREENING FOR OSTEOPOROSIS-FRACTURE PATIENTS CARE! THREE YEAR FOLLOW – UP OF 239 FRACTURE PATIENTS FROM A PROSPECTIVE AND CONSECUTIVE OSTEOPOROSIS SCREENING PROGRAM**  
J. Åstrand\*<sup>1</sup>, M. Tägil<sup>1</sup>  
<sup>1</sup>*Department of Orthopaedics, Lund University, Lund, Sweden*
- P450-M RISEDRONATE ONCE A WEEK IS EFFECTIVE IN MEN WITH OSTEOPOROSIS IRRESPECTIVE OF BASELINE TESTOSTERONE LEVEL OR PREVALENT VERTEBRAL FRACTURE STATUS**  
S. Boonen\*<sup>1</sup>, E. S. Orwoll<sup>2</sup>, D. Wenderoth<sup>3</sup>, K. J. Stoner<sup>4</sup>, R. Eusebio<sup>5</sup>, P. D. Delmas<sup>6</sup>  
<sup>1</sup>*Center for Metabolic Bone Diseases, University Hospital Leuven, Leuven, Belgium*, <sup>2</sup>*Oregon Health Science University, Portland, OR, United States*, <sup>3</sup>*Procter & Gamble Pharmaceuticals, Schwalbach, Germany*, <sup>4</sup>*Procter & Gamble Pharmaceuticals, Egham, United Kingdom*, <sup>5</sup>*Procter & Gamble Pharmaceuticals, Mason, OH, United States*, <sup>6</sup>*INSERM Research Unit 403, Lyon, France*
- P453-M PHYSICAL ACTIVITY IN ELDERLY MEN AND WOMEN: ASSOCIATIONS WITH BONE LOSS, MUSCLE STRENGTH, FUNCTIONAL PERFORMANCE AND FRACTURES IN A 10-YEAR PROSPECTIVE POPULATION BASED STUDY**  
R. M. Daly\*<sup>1</sup>, H. G. Ahlborg<sup>2</sup>, K. A. Ringsberg<sup>2</sup>, P. Gardsell<sup>2</sup>, I. Sernbo<sup>2</sup>, M. K. Karlsson<sup>2</sup>  
<sup>1</sup>*Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia*, <sup>2</sup>*Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Lund University, Malmö University Hospital, Malmö, Sweden*
- P456-M DIETARY PROTEIN INFLUENCES INTESTINAL CALCIUM ABSORPTION, PTH PRODUCTION AND PAMIDRONATE EFFECTS**  
V. Dubois-Ferriere\*<sup>1</sup>, R. Dayer<sup>1</sup>, P. Ammann<sup>1</sup>, R. Rizzoli<sup>1</sup>  
<sup>1</sup>*Department of Rehabilitation and Geriatrics, University Hospital of Geneva, Geneva, Switzerland*
- P459-M EVALUATION OF SERUM OSTEOPROTEGERIN MEASUREMENT AS MARKER OF CARDIOVASCULAR RISK IN POSTMENOPAUSAL WOMEN**  
D. Fernández-García\*<sup>1</sup>, A. Sebastián-Ochoa<sup>2</sup>, R. Reyes-García<sup>2</sup>, G. Alonso-García<sup>2</sup>, P. Rozas-Moreno<sup>2</sup>, M. Muñoz-Torres<sup>2</sup>  
<sup>1</sup>*Endocrinology Division, Virgen de la Victoria University Hospital, Malaga*, <sup>2</sup>*Endocrinology Division, San Cecilio University Hospital, Granada, Spain*
- P462-M HOSPITALIZATION AND THE RISK OF FRACTURE IN HEALTHY OLDER ADULTS**  
R. L. Gardner\*<sup>1</sup>, F. Harris<sup>2</sup>, S. R. Cummings<sup>3</sup>  
<sup>1</sup>*Department of Medicine, University of California, San Francisco*, <sup>2</sup>*Prevention Sciences Group, University of California San Francisco*, <sup>3</sup>*San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, United States*

**P465-M CALCIFIED LARGE ARTERIES, OSTEOPOROSIS& ACUTE STROKE. WHAT IS THE RELATIONSHIP?**

H. S. Hamoud\*<sup>1</sup>, H. M. Hosein<sup>2</sup>, G. A. Elkheshen<sup>3</sup>  
<sup>1</sup>Rheumatology, <sup>2</sup>Neurology, <sup>3</sup>Clinical Pathology, Alazhar University, Nasr City, Egypt

**P468-M MINERAL WATER AND ALCOHOL CONSUMPTION ARE ASSOCIATED WITH BODY WEIGHT AND BONE, RESPECTIVELY, IN OLDER CROATIAN WOMEN**

S. Cvijetic<sup>1</sup>, I. Colic-Baric<sup>2</sup>, I. Cecic<sup>2</sup>, M. Saric<sup>3</sup>, Z. Crncevic-Orlic<sup>4</sup>, M. Blanusa<sup>1</sup>, J. Z. Ilich\*<sup>5</sup>  
<sup>1</sup>Institute for Medical Research and Occupational Health, <sup>2</sup>Food Technology and Biotechnology, University of Zagreb, <sup>3</sup>Clinical Hospital Centre, Zagreb, <sup>4</sup>Endocrinology, Clinical Hospital, Rijeka, Croatia, <sup>5</sup>Nutrition, Food and Exercise Sciences, Florida State University, Tallahassee, United States

**P471-M GENDER DIFFERENCES IN CALCIUM HOMEOSTASIS: A REFLECTION OF AGING?**

W. N. H. Koek\*<sup>1</sup>, B. C. J. van der Eerden<sup>1</sup>, Y. B. de Rijke<sup>2</sup>, F. Rivadeneira<sup>1</sup>, M. C. Zillikens<sup>1</sup>, H. A. P. Pols<sup>1</sup>, J. P. T. M. van Leeuwen<sup>1</sup>  
<sup>1</sup>Internal Medicine, <sup>2</sup>Clinical Chemistry Laboratory, Erasmus Medical Centre, Rotterdam, Netherlands

**P474-M BODY COMPOSITION AND ANTHROPOMETRICS FACTORS AS DETERMINANTS OF PHALANGEAL BONE ULTRASOUND IN WOMEN**

M. L. Canal-Macias<sup>1</sup>, J. M. Lavado-Garcia\*<sup>2</sup>, C. Costa-Fernandez<sup>1</sup>, G. Tellez-Peralta<sup>2</sup>, N. Gonzalez-Amador<sup>1</sup>, J. D. Pedrera-Zamorano<sup>1</sup>  
<sup>1</sup>Department of Nursing, <sup>2</sup>Department of Medicine I, Universidad de Extremadura, Caceres, Spain

**P477-M DO MATERNAL ANTECEDENTS OF FRAGILE PERIPHERAL FRACTURES INFLUENCE YOUNG WOMEN'S BONE MASS?**

R. Moruno Garcia\*<sup>1</sup>, R. Fernandez Ojeda<sup>1</sup>, M. Miranda Garcia<sup>1</sup>, M. Montoya Garcia<sup>1</sup>, M. Vazquez Gamez<sup>1</sup>, M. Giner Garcia<sup>1</sup>, M. Gomez de Tejada<sup>1</sup>, R. Perez Cano<sup>1</sup>  
<sup>1</sup>Internal Medicine, University Hospital, Sevilla, Spain

**P480-M LOW TSH LEVEL AND BONE IN IODINE DEFICIENCY REGION**

M. R. Nekrasova\*<sup>1</sup>, L. A. Suplotova<sup>1</sup>  
<sup>1</sup>Postgraduate Endocrinology Course, Tyumen Medical Academy, Tyumen, Russian Federation

**P483-M PREVALENCE OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN ATTENDED IN A PRIMARY CARE CENTER OF SPAIN. THE CAMARGO COHORT STUDY**

J. M. Olmos\*<sup>1</sup>, E. Obregón<sup>2</sup>, C. Valero<sup>1</sup>, J. Martínez<sup>1</sup>, J. L. Hernández<sup>1</sup>, G. Pinedo<sup>2</sup>, D. Nan<sup>1</sup>, C. Ramos<sup>2</sup>, J. González-Macías<sup>1</sup>  
<sup>1</sup>Internal Medicine, Hospital Universitario Marqués de Valdecilla. Universidad de Cantabria, <sup>2</sup>Centro de Salud "José Barros". Camargo, Universidad De Cantabria, Santander, Spain

**P486-M A LOW LEVEL OF VITAMIN D IS A STRONG RISK FACTOR FOR HIP FRACTURES IN OLDER WOMEN IN NORTHERN SWEDEN – THE UFO STUDY**

U. Pettersson\*<sup>1</sup>, P. Nordström<sup>2</sup>, M. Neovius<sup>3</sup>, O. Svensson<sup>4</sup>, G. Hallmans<sup>5</sup>  
<sup>1</sup>Clinical Pharmacology, Department of Pharmacology and Clinical Neuroscience, <sup>2</sup>Geriatric Medicine, Department of Community Medicine and Rehabilitation, Umeå, <sup>3</sup>Obesity Unit, Karolinska University Hospital, Stockholm, <sup>4</sup>Orthopedics, Department of Surgical and Perioperative Sciences, <sup>5</sup>Nutritional Research, Department of Public Health and Clinical Medicine, Umeå, Sweden

**P489-M USE OF ANTIPSYCHOTICS AND RISK OF HIP/FEMUR FRACTURES: A POPULATION BASED CASE-CONTROL STUDY**

S. Pouwels\*<sup>1</sup>, F. de Vries<sup>1</sup>, A. C. G. Egberts<sup>1</sup>, H. G. M. Leufkens<sup>1</sup>, T. P. van Staa<sup>2</sup>  
<sup>1</sup>Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands, <sup>2</sup>Medical Research Council, Environmental Epidemiology Unit, Southampton, United Kingdom

**P492-M DIETARY INTAKE OF FOLATE BUT NOT VITAMIN B12 IS ASSOCIATED WITH INCREASED BONE MINERAL DENSITY 5-YEARS AFTER THE MENOPAUSE: RESULTS FROM A 10 YEAR FOLLOW-UP STUDY IN EARLY POSTMENOPAUSAL WOMEN**

L. Rejnmark\*<sup>1</sup>, P. Vestergaard<sup>1</sup>, P. Charles<sup>1</sup>, P. Hermann<sup>2</sup>, C. Brot<sup>3</sup>, P. Eiken<sup>4</sup>, L. Mosekilde<sup>1</sup>  
<sup>1</sup>Dept of Endocrinology and Metabolism C, University Hospital of Aarhus, Aarhus, <sup>2</sup>Dept. of Endocrinology, Odense University Hospital, Odense, <sup>3</sup>The Osteoporosis Research Centre, Hvidovre Hospital, Hvidovre, <sup>4</sup>Dept. of Endocrinology and Clinical Physiology and Nuclear Medicine, Hilleroed Hospital, Hilleroed, Denmark

**P495-M STUDY OF OPG/ RANKL SYSTEM IN HUMAN PRIMARY OSTEOBLAST CULTURES IN PATIENTS WITH OSTEOPOROSIS. INFLUENCE OF ESTRADIOL AND VITAMIN D**

M. Rios Moreno<sup>1</sup>, M. Giner Garcia<sup>1</sup>, M. Montoya Garcia\*<sup>1</sup>, L. Najji<sup>1</sup>, M. Vazquez Gamez<sup>1</sup>, R. Moruno Garcia<sup>1</sup>, M. Miranda Garcia<sup>1</sup>, R. Perez Cano<sup>1</sup>

<sup>1</sup>*Internal Medicine, University Hospital, Sevilla, Spain*

**P498-M BONE MINERAL DENSITY AND INCIDENCE OF HIP FRACTURES – SECULAR TRENDS OVER A DECADE**

B. E. Rosengren\*<sup>1</sup>, R. M. Daly<sup>2</sup>, M. K. Karlsson<sup>1</sup>, P. G. Gärdsell<sup>1</sup>, I. Sernbo<sup>1</sup>, H. G. Ahlborg<sup>1</sup>

<sup>1</sup>*Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Lund University, Malmö University Hospital, Malmö, Sweden,* <sup>2</sup>*Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences Deakin University, Melbourne, Australia*

**P501-M INCREASED MORTALITY IN PATIENTS WITH A HIP FRACTURE – CAUSE OR CONSEQUENCE?**

P. Vestergaard\*<sup>1</sup>, L. Rejnmark<sup>2</sup>, L. Mosekilde<sup>2</sup>

<sup>1</sup>*The Osteoporosis Clinic,* <sup>2</sup>*Department of Endocrinology and Metabolism C, Aarhus Amtssygehus, Aarhus, Denmark*

**P504-M WHICH IS THE BEST ROI TO DETECT AGE-RELATED BMD CHANGES?**

J. Wendlova\*<sup>1</sup>

<sup>1</sup>*University Hospital and Policlinic, Osteological Unit, Bratislava, Slovakia*

**P507-M OSTEOPOROSIS AND OSTEOARTHRITIS: IS OSTEOPOROSIS A PREDICTOR OF THE INCIDENCE OF OSTEOARTHRITIS, OR VICE-VERSA?**

N. Yoshimura\*<sup>1</sup>, S. Muraki<sup>2</sup>, H. Oka<sup>1</sup>, A. Mabuchi<sup>2</sup>, H. Kawaguchi<sup>3</sup>, K. Nakamura<sup>3</sup>

<sup>1</sup>*Department of Joint Disease Research,* <sup>2</sup>*Department of Clinical Motor System Medicine, 22nd Century Medical and Research Center, The University of Tokyo,* <sup>3</sup>*Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-Ku, Tokyo, Japan*